Archive for May, 2020

The surgery was scheduled for March 20. I had already had pretty in-depth discussions with nurses from the surgery and anesthesia departments about all of the preoperative details. But on March 18, I got a call from the physicians assistant who works with my surgeon, and I knew what she was going to say as soon as I heard her voice: Surgery on my reconstructed breast had been canceled due to COVID-19.

Since then, Ive had a unilateral mastectomy, five months of chemotherapy, 28 radiation treatments, and four years of hormone blockers. Ive had no evidence of disease since my mastectomy on June 19, 2015.

Ive also had three different types of breast reconstruction. First, in March 2016, I had reconstruction with a breast implant and a breast reduction on my left breast to match its size. But the implant never really settled well. It was very highit didn't look very natural next to my other breast. And it was very tightthe muscles in my chest felt like they were seizing up or cramping a lot, and it was even uncomfortable to lay on my stomach to go to sleep.

So then, in May 2019, I had something called DIEP flap reconstruction, which is when they basically take your belly, disconnect it from its blood supply, and reconnect it to the chest as new breast tissue. (During that surgery, we learned that the implant had actually ruptured a little bit.)

Almost all DIEP flap surgeries are successful, but mine wasnt. About two weeks after the surgery, I met with my surgeon, and as soon as he saw the tissue, his face fell. The tissue was dead. So a week or two after that, I had to basically have another mastectomy to get the new tissue removed.

Finally, I had whats known as TUG flap reconstruction in November 2019. It involved a third surgeon and using the inner portion of my left thigh. It worked! The only issue is that the breast is really small because its from my inner thigh, so it's basically like an A cup, compared to my native breast, which is now like a D. (Before, I had double Ds. I had a great rack, I'm not gonna lie.)

So I'm pretty lopsided now. Im expecting to still have one or two more fat transfers, probably from my stomach, to my reconstructed breast, and then probably another reduction on my native breast so that they can match in size.

Since my TUG flap, my surgeon took a job out of the country, but we had this little window where he was going to be back to do some surgeries and I was going to be on spring break from both my teaching job and being a PhD student.

At the time, the pandemic was starting to ramp up in Iowa, where I live. The university I teach for had just closed for the rest of the semester. In fact, I was really debating internally with myself: Is it moral for me to get the surgery at this point and take up protective personal equipment (PPE) and resources? Is it safe for the staff there? Is it safe for me? So I was a little relieved when they made the call for me.

After that, I didnt hear from the hospital until mid-May (of course, theyve had bigger issues to deal with), when the physicians assistant called to tell me that my next surgery will take place on June 5.

She assured me that the hospital has enough PPE and is well prepared. My husband will have to drop me off and pick me up without entering the hospital, and the thought of waiting for surgery alone is daunting, to say the least. Ill also have to drive two hours one-way to Iowa City for a COVID-19 throat swab test the day before my surgery because the test has to be done within the University of Iowa Hospitals and Clinics system. Its inconvenient, but I'm happy to do it and keep my medical team safe.

But Im feeling a little disappointed in a selfish way that I have had to wait longer to have my breast reconstructed. Im just really ready to have my body put back together. One of the worst parts of this surgery being delayed is that we're not just holding on one surgery; theres going to be a series of surgeries and recoveries that follow. So its frustrating to not know what the timeline is going to look like and to not have an idea of what my body is going to look or feel like months or even a year from now.

I have to be on hormone blockers for five years before I can pause them to try to have kids because I had estrogen receptor (ER)-positive and progesterone receptor (PR)-positive breast cancer, which means the cancer cells grow in response to estrogen and progesterone. So when I finish those up in 2021 and my husband and I are 35, I want to get the ball rolling with IVF as soon as I can.

The goal was to have the reconstructions complete by this summer. Then I could have until the end of next year to just exist in my body without having it be something that needs to be fixed or manipulated or changed, have a short amount of time to travel, to swim, to work out normallybecause rumor has it pregnancy is kind of hard.

While the fat transfers are a quicker recovery, the reduction on my native breast is a longer ordeal, and I'm trying not to miss any more of my job or sacrifice working on my PhD. I dont think it will be possible to squeeze in multiple fat transfers and a reduction on my native breast in the next few months, which means the next big chunks of time I have arent until this coming winter break and next summer, or maybe spring break next year. As a result, Ill probably have to either push back IVF or go straight from the surgery into trying to be pregnant.

Plus, experts are predicting a second wave of outbreaks, so really any concept of a timeframe I had is out the window. I think I'm just going to have to undergo my future procedures based on the surgeon's availability, breaks in the school year, and the waves of this pandemic.

Before cancer, you've got all the options in the world open to you, and then cancer goes, Nope, youve got a limited set of choices. And to have that reduced even furtheron one hand, I'm used to it; on the other hand, its getting really old. Im just tired of having cancer and these surgeries dictate the pattern of my life.

But then you get through that terror of treatment, and you start to see the light at the end of the tunnel. You go, Oh, wait, my appearance does matter to me. Im still a young woman, and I still want to be able to wear a sports bra that supports me. I want to be able to buy a wedding dress that I look nice in.

As you start to get back to your normal life, you start to remember those priorities. Reconstruction seems like its just a cosmetic thing, like it's not a big deal. But it changes your mental health, it changes your outlook, and it changes in the way your muscles move and the balance of weight across your chest.

I joke a lot about cancerthats how I copeand so I get why people say that. And yes, technically, the Womens Health and Cancer Rights Act of 1998 says insurance must also cover expenses related to the reconstruction of a breast after a mastectomy. But I would much rather not have gone through cancer than get a free boob job. Its not an equal tradeoffand I have paid so, so dearly, both literally and figuratively, in many other ways.

Reconstruction is a way of feeling normal again and not having this reminder every time I take a shower, every time I dress, every time I buy new clothes, of what Ive been throughand all the work that still has to be done.

Reconstruction is a way of trying to put the trauma of the past five years behind me. And then, even if Im not perfectly happy with my body, I could say, Okay, this is it. I know what I've got to work with, and I could start to embrace it. I could move forward. Right now, its more like being stuck in limbo.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

See the article here:
My Breast Reconstruction Surgery Was Delayed Because Of COVID-19 - Women's Health

Left foot forward. Right foot forward. While that may well be the mantra playing in 18-year-old Caster Semenyas head as she flies furiously down the length of the track towards the finish line, the spectators watching her would be lucky to be able to distinguish between her feet as she runs. Her high speed reduces her muscular figure clad in a South-African-colored uniform to a blur of green and yellow as she finishes almost a full second before her closest opponent at the World Championships in the 800 meter race.

Semenya didnt just win her event she dominated it.

But later that fateful night in 2009, instead of being celebrated for the young phenom that she had trained arduously to become, Semenya came under fire for potentially having an unfair advantage as the public began to question her biological sex. The intrusive testing and inquisitions that followed affected Semenyas ability to compete, but she did her best to hold her head high and carry on as people picked apart her prowess. Semenyas case was just one of many that deals with the complicated role of gender in sports, a topic that becomes increasingly relevant as athletic science improves and athletes of all genders become faster and stronger than ever before.

When people think of sports, their mind often divides mens sports and womens sports into two separate entities, with the athletes within them as strictly binary. Sports have been categorized this way throughout history with the intention of ensuring that competition that ensues will be fair. But how do we define fair, and will this rigid separation continue to be the norm in the future?

In some sports, such as distance swimming, the average percent difference between men and womens times is a slim 5.5%, according to a 2010 study in The Journal of Sports Science and Medicine. In other sports, such as weightlifting, this difference is more significant at 36.8% according to the same source. Because each sport is unique in the physical challenge it presents to athletes, the same standards for legislation and rules regarding gender and fairness cannot be applied universally.

Recently, there has been an increase in discussion surrounding transgender athletes competing in the gender category that best matches their gender identity. While some push back against trans inclusion in situations such as the Idaho bill passed in March that enforces genital and hormonal testing of athletes, others fight for equality in sport. Harvard graduate Schuyler Bailar a trans swimmer who was accepted onto the mens team and found great success and joy in living life as his most authentic self is one of the athletes leading the fight for gender inclusivity in sports. The role that gender plays in sports is already complexthe way gender and sports will interact in the future is even more so.

Despite a social movement towards increased transgender inclusion and a general heightened understanding of what it means to be transgender, many major sports leagues, such as USA Powerlifting, have chosen to keep their original policies in place. In a statement of the organizations transgender participation policy, the USA Powerlifting league cited both the physical advantage of males and a ban on the androgens often used to transition from female to male as reasons for their stance.

While the term discrimination is used to catch the attention of the public, it is most often misused, the statement read. We are a sports organization with rules and policies. They apply to everyone to provide a level playing field.

While some question whether the USA Powerlifting policies are discriminatory against transgender athletes, the organization said it is fair in a sport largely based on physical strength and compared gender discrimination to policies surrounding age restrictions.

This bill attempts to solve a problem that does not exist while slamming the door shut for transgender student athletes to fully participate in their school communities.

Kathy Griesmeyer

At the high school level, some athletes have protested transgender participation in the gender category of their choice. Recently, at a high school in Connecticut, the families of female track runners filed a lawsuit against the participation of transgender athletes in womens sports, arguing that their female children competing against runners with male anatomy could hinder their personal chances of earning track titles and scholarships.

Those who share the same opinion as those parents have formed conservative groups and are supported by legislators throughout the states that are looking to ban participation of transgender athletes in both mens and womens sports. For example, the Idaho state Senate recently passed Republican-sponsored bill 24-11. If signed, this bill would prohibit both trans and intersex girls from competing in the girls heats of high school and college sports.

If a female athletes sex is questioned by a coach, parent, or administration of the other team, the future of that athletes participation depends on if their biological sex is confirmed by a signed physicians statement that shall indicate the students sex based solely on: The students internal and external reproductive anatomy; the students normal endogenously produced levels of testosterone; an analysis of the studentsgenetic makeup, according to the bill.

This bill fails to acknowledge that the inclusion and acceptance of transgender people and their identity is extremely important to their well being, both physically and mentally. By reducing someone to their biological sex characteristics, one is blatantly disregarding their internal identity.

Additionally, this bill only targets female athletes, requiring them to go the extra step if their sex status is questioned in order to play their sport, while their male counterparts do not have to endure this same burden. This suggests that, should a woman have success in an athletic event, her success may be attributed to genetic alterations rather than talent.

Kathy Griesmyer, a policy director with the American Civil Liberties Union of Idaho, is disappointed with this bill, citing that it is intentionally transphobic and that it makes things more difficult for athletes that already face many social hurdles simply for fulfilling their true sense of identity.

This bill attempts to solve a problem that does not exist while slamming the door shut for transgender student athletes to fully participate in their school communities, Griesmyer said in a statement in response to the bill. Idaho has not seen any issues with trans girls competing in the girls sports. This unconstitutional and mean-spirited bill prevents trans girls from finding community and self-esteem in sports, and will certainly result in litigation to defend the civil rights of Idahos transgender community.

In addition to being transphobic, this bill is an invasion of the athletes privacy and puts power in the hands of coaches or parents who may use it to place their competitors at a harsh disadvantage.

In a similar proposition, legislation announced in January could prevent transgender women in Arizona from participating in athletics teams based on their gender identity, requiring some females athletes to provide a doctors note stating their biological sex in order for them to compete in their sport.

However, this rule only applies to womens sport and not to male counterpart sports. The vast majority of the arguments surrounding barring transitioned athletes center solely on male-to-female athletes. Those critics cite the biological differences between men and women that, they claim, could lead to significant competitive advantages for male athletes. Most of these changes take place during puberty: a biological male undergoing puberty will see a host of changes due to their significantly elevated testosterone levels compared with biological females. According to a study comparing female to male testosterone, an adult male will have seven to eight times the natural testosterone coursing through a womans body on average.

This testosterone is accompanied by scores of physiological changes, among them larger muscles, denser bones and a higher proportion of lean body massits these traits that lead to the bigger, faster, stronger notion surrounding male athletes.

While transitioning to female often involves the use of testosterone suppressants and estrogen, most in favor of barring trans athletes argue that these measures dont reverse the increased bone density, superior musculature, and other characteristics of male puberty.

So despite the fact that female-to-male athletes who choose to undergo hormone therapy treatment will also have elevated testosterone levels, this isnt seen as a threat: the vast majority of benefits will be derived from a biological male puberty, not from an addition of testosterone to a body thats undergone female puberty.

But, of course, thats not always the case. A 2016 Washington Post article examining the trans advantage cites that after a year of hormone therapy, female trans distance runners completely lose their speed advantage over cisgender women. Similarly, individuals like Nancy Barto, an Arizona state representative, recognize that regardless of whether a male-to-female athlete will have a greater advantage in sports than a female-to-male athlete, legislature that targets women specifically cis or otherwise puts up barriers to prevent their participation. This type of legislature in sport is counterproductive, introducing yet another in a long line of historical roadblocks for female athletes.

When this is allowed, it discourages female participation in athletics and, worse, it can result in women and girls being denied crucial educational and financial opportunities, Barto said in an interview with NBC News.

The recent passage of such legislation such as the bill signed by Idahos governor on March 30 raises questions about what, exactly, constitutes someone as being transgender. Legislators such as Representative Barbara Ehardt, a sponsor of the bill passed in Idaho, have said that genital exams and genetic and hormone testing could easily determine an athletes sex. However, in reality, sex testing may not be that simple, as it is difficult to come up with metrics to objectively distinguish between different sexes.

Some of the sex testing methods that Ehardt cited may even produce contradictory results. At the 1966 European Track and Field Championships in Budapest, Polish sprinter Ewa Kobukowska passed a genital exam and qualified as female. The following year, Kobukowska failed a chromosomal test, and was barred from participating in the European Cup womens track and field competition in Kiev. An analysis later found that she had a set of XXY chromosomes.

A similar issue arises when it comes to hormone testing. The International Association of Athletics Federation, which sets testosterone limits for women in racing events ranging from the 400-meter to one-mile race, bans athletes who produce abnormally-high levels of testosterone from participating in womens sports.

In 2011, the IAAF set the limit for womens testosterone levels at 10 nanomoles per liter of blood, widely considered the lower end of the typical testosterone level among males. This limit barred Dutee Chand, an Indian sprinter who naturally produces high levels of testosterone, from competition. Chand later won an appeal against her ban; the court agreed with Chand that there was no scientific evidence linking high testosterone levels to better athletic performance. The IAAF commissioned a study in 2017 and justified with data that was highly scrutinized lowered the limit to five nanomoles per liter seven years later, a change that was meant to ensure a level playing field for athletes, IAAF President Sebastian Coe said. Critics argued that the data was flawed, and urged the IAAF to retract the study, which was published in the British Journal of Sports Medicine.

However, the IAAF stood firmly behind its study and said it would not retract the paper. Our evidence and data show that testosterone, either naturally produced or artificially inserted into the body, provides significant performance advantages in female athletes, Coe said. The press release goes on to state that most females have testosterone levels of between 0.12 to 1.79 nanomoles per liter, and that no females testosterone level would exceed the IAAFs new limit unless they had disorders of sex development or a tumor.

An example of a female athlete with higher than usual levels of testosterone is track champion Caster Semenya of South Africa. She began running seriously at age 12, and by the time she became an adult, she was competing in the Olympics. Due to her incredible success and ability, suspicion arose regarding Semenyas biological sex and levels of testosterone. She soon found herself the target of an extremely intrusive media investigation and was eventually barred from competing; after an investigation discovered that she was born with XY chromosomes, Semenyas genetic makeup was ruled an unfair advantage over her competition.

On August 19, 2009, Semenya won the 800-meter event in the World Championship by a landslide, but following this impressive feat came a seemingly never ending public investigation into her biological sex and sex characteristics.

Along with stripping Semenya of any type of celebration or praise for her accomplishments, the public reduced her feats to her gender. The scrutiny Semenya endured is disproportionate to her situation, as she is seconds off the world record and is relatively competitive with other female athletes, disproving the idea that she has an unfair advantage she is simply talented at what she does.

Typically, it is women who endure accusations of this nature. Michael Phelpss abnormally long wingspan is never labeled as an unfair advantage; it is simply a tool that makes him successful. Most professional basketball players are extremely tall compared to the general population, making them genetic oddities, and this is never labeled as an unfair advantage. Yao Ming, for instance, is a staggering 76 tall, a height thats inspired countless conspiracy theories about whether the star was bred in a lab rather than born to his 63 mother and 67 father. Tinfoil hats aside, Mings height enabled him to tower over even his fellow NBA competitors. Ming is nearly a full foot taller than the average NBA player, who stands at 67, and nearly two feet taller than the average American male, who stands at 59, which gives him a clear competitive advantage based on his genetics. And instead of protesting Usain Bolt, society hails him as the fastest man in the world, despite his body being described as built for speed due to his abnormal proportions. In a BBC News article, former Great Britain sprinter Craig Pickering said, Bolt is a genetic freak because being 65 tall means he shouldnt be able to do what he does at the speed he does given the length of his legs.

Along with stripping Semenya of any type of celebration or praise for her accomplishments, the public reduced her to her gender.

The main goal of most professional athletes is to be the best they can, so why was Semenya punished for her gift? The examples listed above are few compared to the gifted male athletes celebrated for the genetic gifts that enable them to compete leaps and bounds ahead of most athletes. And the countless examples seem to point to one central notion: men who are good at what they do are not held to the same unreasonable standards or stigma as their female counterparts.

Although Semenyas case has gained notoriety, she is not the first female athlete to face restrictions from her sport when her performances were deemed, essentially, too good to be true. Maria Jos Martnez-Patio, an internationally-recognized hurdler turned college professor, has a history that eerily parallels that of Semenya, so much so that Martnez-Patio calls herself the Semenya of the 1980s, according to a profile with the United Kingdoms Times. Martnez-Patio faced little scrutiny or public attention initially; at 22, she was given a certificate of femininity after passing a sex test the title is often awarded after enduring humiliating and intrusive tests such as gynecological exams, MRIs, and ultrasounds enabling her to advance to the quarter finals of the 100-meter hurdles at the world championships in Helsinki.

But in 1985, her troubles began.

At the World University Games, a new test karyotype analysis that examined her chromosomes directly found that she had an XY 46th chromosome, the chromosomal pattern typical of a biological male. Martnez-Patios story was more complex than her chromosomes she has androgen insensitivity syndrome which means her body doesnt respond to testosterone in a typical fashion, so any advantage she was perceived to have was likely naturally negated but the storm of public backlash that poured down on her was indifferent to that fact. After her test, Martnez-Patio was ruled ineligible to participate in femaleathletics, and even encouraged to fake an injury to leave quietly. She suddenly found herself barred from the sport shed played and loved all her life and newly privy to information regarding her sex that would leave anyones head spinning if not reconsidering what theyd thought was the truth about their gender their entire life. If the sudden onslaught that had struck Martnez-Patio wasnt already enough, the humiliation and shame of being pushed to lie, to leave gracefully not to make a scene was the final straw. Despite her initial compliance with the injury scheme, Martnez-Patio chose to fight back. In 1986, despite the public media skewering shed endured, she entered the Spanish national championships 60-meter hurdles event. She was told she had two options: withdraw from the event discreetly, or face public condemnation. She chose the latter. After competing and winning, she was stripped of her scholarship and athletic residency, and faced consequences in her private life that were far more hurtful than any Spanish press article.

In The Times article, Martnez-Patio describes how she suffered after the test. I lost my boyfriend because all the media said I was a man, Martnez-Patio said. On many occasions, I thought the best thing was to die because I could not stand so much suffering and injustice. I had to leave my residence in a high-performance center in Madrid within 24 hours. I was on the street. The most complicated thing is having to publicly demonstrate your status as a woman before the whole world. You feel as if everyone is talking about the amount of woman that you are. And this stigma accompanies you for the rest of your life.

Similarly to Martnez-Patios situation, when she was told to cease competing until her chromosomal test results were returned, the International Amateur Athletic Federation, or IAAF, requested Semenya to refrain from competing until there was a definitive conclusion from sex verification tests. As this all occurred, Semenya, her family and her team upheld the statement that she was biologically female and had identified as a woman since birth, regardless of her abnormal hormone levels.

However, this type of testing is not as accurate or conclusive as many hoped it would be. According to many studies and Dr. Gerald Conway, an endocrinologist who worked on the study of Semenyas hormones, while it is true that higher-than-usual levels of testosterone can give an individual an advantage in sport, this is not always the case.

There is an advantage to exposure to testosterone, which is why people use testosterone as an anabolic steroid, Conway said. There are natural conditions, where women normally have more testosterone in circulation, and they would have a biological advantage in many sports arenas.

But the quantitative level of testosterone in ones blood isnt the end all be all, as some women do not react to having high levels of the hormone because their bodies simply dont recognize it.

Katrina Karkazis, a cultural anthropologist and research fellow at Yale, co-authored the book Testosterone: An Unauthorised Biography with Rebecca Jordan-Young, a sociomedical scientist. In it, Karkazis and Jordan-Young critique and dismantle the previously believed effects testosterone has on the body.

In an interview with The Guardian, Karkazis discussed misconceptions about the actual impact testosterone can have on an athlete.

Testosterone is a very dynamic hormone, Karkazis said. Its actually responsive to social cues and situations. For example, if a coach gives you positive feedback, that can raise your testosterone level Where we run into trouble is trying to make comparisons across individuals based on testosterone levels. Sometimes its individuals with lower testosterone who do better. So its not as simple as saying more testosterone equals better performance.

Schuyler Bailar made history as the first openly transgender swimmer in the NCAA. As a member of the graduating class of 2019 from Harvard, the Virginia native took a gap year after high school during which he came out as transgender. After becoming a star swimmer in high school, Bailar had been recruited to swim for the womens team at Harvard, although after coming out he was unsure if he would be able to swim on the mens team once his education at Harvard began.

In an interview on the Ellen Show, Bailar said that while he has not been as competitive in mens heats in comparison to the dominance he showed when racing against women, he doesnt mind. Bailar admits that while he is no longer placing first, he is holding his own in races, defying people who support barring trans athletes from existing as themselves.

Im not winning anything, but I think Im not awful, Bailar said with a smile on his face. I keep up with my teammates and I keep up with the people around me, but Im not winning anything like I used to and thats definitely humbling.

While some people may argue that trans athletes fight to change which gender category they compete in for an advantage or other external reasons, Bailar is simply living life in a way that feels true to himself and because the sport is important to him. Along with being a swimmer, Bailar has become a public speaker, and aims to raise awareness about transgender youth in sports.

It [not winning] has helped me develop something I was working on before, which was learning to love swimming just for swimming, and I think that theres a lot of other kinds of glory in that, Bailar said.

I was just ecstatic and it was as much glory as I wouldve gotten in first place. Probably more, because I was myself.

Schuyler Bailar

Bailar has found that having the support of his team and improving on his own personal times can be just as exciting and rewarding as a medal.

In my last meet, I got sixteenth place, which obviously is not first place, Bailar said with a laugh. But the whole team was on the side of the deck and they jumped up and were screaming for me because I dropped a lot of time from my best, so I did really well relative to myself, and I was just ecstatic and it was as much glory as I wouldve gotten in first place. Probably more, because I was myself.

Elizabeth Edwards, an 18-year-old senior at the Urban School of San Francisco and a transgender woman, believes legislation which requires sex testing doesnt work and unfairly discriminates against transgender women like herself.

The requirement of gender reassignment surgery is ridiculous, especially considering the absurdly strict medical standards currently held in the US to qualify trans people to undergo them, Edwards said. Also, sex verification standards leads without fail to unfair standards of gender expression normativity that bear down on cis people, and result in cis people being disqualified on bases of uniquely high/low chemical levels that result from normal variance in such factors across the cisgender population.

A study conducted by researchers from the Department of Molecular and Cell Biology and Biochemistry at Brown University found that as many as 2% of the population have traits which deviate from the ideal male or female, including hormone levels and the structure of the internal genital duct systems and external genitalia. This seems to suggest that sex testing would not necessarily be as straightforward as critics suggest.

According to Edwards, at the professional level, the highest reasonable requirement should be proof that an athlete has undergone hormone reduction therapy for 18 months.

By that point, trans and cis people are chemically identical, and such quote-unquote biological dis/advantages such as bone density will have fallen to the wayside, Edwards said.

While research on this subject has hardly reached a consensus, a meta-analysis of eight research articles conducted by researchers from the Nottingham Centre for Gender Dysphoria and Loughborough University concluded that there is no evidence that hormones such as testosterone give transgender female athletes an advantage.

The analysis also reviewed 31 sport policies from various national and international competitions and found that rules restricting participation from transgender athletes discourage transgender athletes from participating in sports.

Within competitive sport, the athletic advantage transgender athletes are perceived to have appears to have been overinterpreted by many sport organisations around the world, which has had a negative effect on the experiences of this population, the analysis reads.

The researchers also write that sports organizations need to improve their policies to be more inclusive.

Given the established mental and physical health benefits of engaging in physical activity and sport, the barriers transgender people experience are a significant limitation to the promotion of healthy behaviours in transgender individuals, the analysis reads.

Kay Svenson, a Paly alum and recent graduate of Wellesley college, is a trans activist and believes that trans people, like all people, have the right to be treated in accordance with their gender identity, and this includes sports.

Sex-based discrimination is prohibited under Title IX, and that amendment is not up to the free interpretation of the (potentially transphobic) governing bodies of the state or local school district, Svenson said. We need to work harder to ensure that differences in birth anatomy do not shape our definition of athletic fairness.

Svenson believes that it is important that transgender people have the means and support to pursue their personal athletic careers, free of judgment.

Trans athletes have just as much of a right as cis athletes do to compete in the gender category that they identify with, Svenson said.

While there is no explicitly correct answer or proposed set of regulations surrounding the role of gender identity in sports today, if athletes and fans alike continue to ask hard questions respectfully and work towards giving everyone the opportunities to enjoy sports, compete as themselves, and make sure matches remains competitive, it will be a victory for everyone. Nonetheless, as gender identity and societal views surrounding the gender spectrum become more well understood and all-encompassing, the issues described will only become more complex. Its time to have conversations about this topic now so were ready for the more complex questions later.

Read more from the original source:
On the Basis of Gender - The Viking Magazine

Life was hard enough for the one-third of Americans who had wrestled with anxiety prior to the COVID-19 pandemic.

Now, the disease that has killed almost 100,00 in the United States, left millions unemployed, and socially distanced many people from friends and family is causing fear, isolation, and financial distressa mentally toxic combination for many.

In fact, almost half of adults in the United States, 45 percent, say that worry and stress related to the coronavirus and the resulting economic downturn are hurting their mental health, according to a study by the Kaiser Family Foundation.

We asked Harvard Business School experts who study well-being to share strategies for coping with this unsettling period to prevent the coronavirus blues from taking a huge toll, both personally and professionally.

You're not going to be a good [business] leader unless you know how to lead yourself, says Arthur C. Brooks, Arthur C. Patterson Faculty Fellow. You're not going to be a good entrepreneur unless you see that your life is your enterprise; your life is your startup.

Heres what Brooks and four other HBS experts recommend:

Focus on the here and now. In a matter of weeks, as the coronavirus rapidly began taking an increasing number of lives and livelihoods, people suddenly felt as if their future became murkier.

When uncertainty and disappointment morph into fear, people often try to gather information that might help them reduce their risksincluding spending hours reading or watching the news.

Rather than ruminating on the virus and replaying possible future outcomes in our minds, its best to let go of the notion that anyone can completely control the COVID-19 fallout and instead focus on today, say Brooks and Leonard A. Schlesinger, the Baker Foundation Professor.

This is such an impermanent state of affairs that we just have to do as best we can, Brooks says.

Make time for introspection. The coronavirus represents a historic inflection point that is likely to forever change us, as did the assassination of President John F. Kennedy and the terrorist attacks on September 11, 2001.

Brooks suggests using this period as an opportunity to take stock of your own life. Does your work reflect your values? Have you let some important relationships languish? Did you give up on a dream too soon?

One of the things that I feel is really important is that people not waste this moment, Brooks says. When something causes you to become introspective, that should be a moment and opportunity for intense personal growth.

Indeed, when we focus our energy on our strengths, we feel more authenticand that increases resilience and happiness, improves relationships, and reduces stress, according to research by Francesca Gino, the Tandon Family Professor of Business Administration. If we take time to reflect on what were good at and enjoy, we may discover that all the meetings we used to hold in the office sucked up too much time or that a trip to the childrens museum wasnt the key to bringing the family joy.

Rather than fighting for ways to get back to our usual routine or even just waiting for this crisis to end, a better approach is to embrace this time, Gino says. We might find new routines and activities that we appreciate more.

Tap into your inner spark of curiosity. Curiosity is critical to learning, innovation, and even higher levels of life satisfaction, so getting inquisitive could help us now. Preliminary results of a study Gino conducted during the coronavirus crisis shows that people with a heightened sense of curiosity feel less stress and approach their days thinking about what they might learn during this strange period, rather than feeling paralyzed by their changed circumstances.

To pique your own curiosity, consider setting regular learning goals, whether its figuring out a challenging piece of software, trying a new recipe, or searching for answers to the deep questions children ask because theyre naturally more curious, given that curiosity peaks at ages four and five.

When my child asks, Why is the sky blue? I turn it around and say, Why do you think its blue? How can we find the answer? Maybe before the pandemic we had places to go and we felt we didnt have a few extra minutes to look for the answers to those questions, says Gino, who has four children. Now we have an opportunity to do just that. Even learning something small can give you pleasure and a sense of accomplishment.

And if the house gets a little messy during a curiosity quest, thats OK. Gino recalls her two-year-old exclaiming it was snowing while scattering salt from an open jar all over the floor, or her young children running around the kitchen, flinging open cabinets, and putting colanders on their heads as hats.

I used to ask them to stop but, at some point, I realized I was contributing negatively to my own curiosity and theirs, she says. Usually, the chaos or mess is not as big or loud as I envisioned it would get. And the joy that comes out of the little mess is significantly higher than the small amount of cleaning you have to do afterward.

Schedule each day. Many parents are caring for their children and guiding their remote learning while trying to do their own jobsand feeling like theyre failing on all fronts. Eventually, thoughts about unfinished work tasks encroach on relaxation time, making people feel as though theyre always working.

Youre trying to stuff too much into a little sack and it keeps tearing open, Brooks says.

He recommends people schedule everything they need or want to do, whether its finishing a presentation or talking a walk. Sticking to the schedule will help restore some work-life balance and reduce cognitive load, freeing up mental bandwidth to efficiently process all the tasks people need to accomplish.

Focus on important projects. When people get stressed, they often look to accomplish tasks that are unimportant but feel urgent in the moment. So they spend their days feeling like theyre putting out small fires everywhere by answering emails and crossing relatively menial obligations off the to-do list.

To relieve time stress, people would benefit by setting aside blocks of time every day or even just once a week to work on the important heavy-lifting projects they put off but that weigh them downwhether personal or work-related, says Assistant Professor of Business Administration Ashley Whillans. If colleagues try to schedule meetings during that time, say no, and turn off alerts so youre not getting pinged with messages while trying to focus. Protect that time at all costs, Whillans says. It will help you feel more in control.

Its also OK to request more time to get work projects done if necessary, since studies show managers are generally willing to extend deadlines when employees ask. Its taking us longer to accomplish tasks right now, so we should ask for the time we reasonably need to get things done, Whillans says.

Gracefully bow out of extraneous activities. Many employers are trying to help their employees unwind by scheduling virtual coffee breaks, lunch gatherings, and happy hours with coworkers. But Whillans says companies should be careful about adding too many obligations to peoples already-full plates, even if their intention is to relieve stress through social interactions. And, if youre on the receiving end of these invitations and can tactfully decline, do it.

Adding more things to peoples schedules is not the way to go. All the video calls are especially exhausting, Whillans says.

Take time off, if you can. The demands of work havent slowed for many. And even in the best of times, people who report greater time scarcitythose who feel overwhelmed by having too much to do with not enough time to do everythingare more anxious and less satisfied with their lives, according to research by Whillans and Michael I. Norton, the Harold M. Brierley Professor of Business Administration.

Workers who are able to take time off and recharge during this disconcerting period will be more engaged when they return.

People often dont take the vacation time they have coming to them, and many are feeling even more hesitant to ask for time off right now. But they are also feeling really burned out, Whillans says. We have all had to do a lot of adapting in a short time, and we dont know when this is going to end. All the things we cant control are emotionally taxing, so, now more than ever, we need to take the personal time we have accumulated.

On days we do work, we should build in mini-mental health breaks to take a walk or enjoy coffee with a family member or friend, virtually or in person. Just taking 10 minutes to slow down can be helpful for our mental health, rather than being constantly in motion, Norton says.

Put your family first. People who stake their self-worth on financial success spend less time with family and feel lonelier as a result, Whillans recent research shows. We need to remember to set work aside and make time to connect in meaningful ways with family and friends, says Whillans, whose partners stressful work as an emergency room physician is a daily reminder to set her priorities straight.

I am really walking the talk in terms of my research right now, she says. The weight of whats going on underscores what really matters. We should be mindful about how we spend our timeand spending time together is much more precious than an abstract paper or phone call I dont need to take. Life is inherently unpredictable and uncontrollable, but what we say yes to are things we can control.

Naturally, emotions may flare when people are confined together. If you want your relationships to outlast the pandemic, resist the urge to express frustration through contempt, whether its a dismissive eye-roll or a sarcastic jab, Brooks says. Research by relationship scholar John M. Gottman found that couples who expressed contempt were more likely to divorce.

Hug it out. Schlesinger and Brooks recommend a simple strategy for relieving tension among friends and families who are quarantining together: Hug each other regularly for 20 seconds. This is the amount of time it takes to boost levels of oxytocinthe so-called love hormonein the brain to peak levels.

If youre lucky enough to have the physical presence of other folks in your house, grab one of them and hug them, Schlesinger says. And if youre social distancing alone, use videoconferencing tools to reach out to family and friends, so that you can look at each other as you talk, since eye contact also lifts oxytocin levels.

Connecting on social media, however, doesnt offer the same benefits. While use of social platforms has increased during the pandemic, with Facebook traffic rising by 50 percent in some countries, people dont get a boost of oxytocin from these interactions. Seeing random photos of happy families or political memes may even have the opposite effect and sap those good feelings. Outside of professional networking, its best to limit social browsing time to 30 minutes a day, Brooks and Schlesinger advise.

Lean on rituals. Continuing with longtime rituals, like making a partners coffee every morning or reading two storybooks to children before bed, can help couples and families bond and provide comfort at a time when so many other aspects of our lives have changed, Norton says.

With little kids, we dont mix up the bedtime ritual. We do the same thing in the same order because we know this is really important to them, Norton says. We think as grownups we dont need rituals anymore, but thats not the case. They help us calm our nerves.

Now people are adapting old ritualsby holding virtual Sunday dinners or gathering for church onlineand inventing new ones by going for walks on the same route every day or designating certain nights to playing games.

Preliminary data from a new study by Norton and HBS doctoral candidate Ximena Garcia-Rada shows more than half of parents have introduced new rituals since the crisis startedand many say they help their families cope. Even rituals that may seem annoying or kids complain about and ask why they have to do them are centering for families, Norton says. People need the familiar things that bond them even more during this crisis.

Rituals can also help employees working from home add boundaries around their workday. When people typically arrive home from work, they often have a corner or a mudroom where they drop their stuff, Norton says. Now many people have work all over the place. He advises storing laptops and work-related materials in a certain spot to mark the end of the workday.

Perhaps most tragically, social distancing has halted many in-person communal grieving rituals like wakes and funerals, adding to the sorrow of people mourning loved ones. Yet, even if the typical ceremonies arent practical right now, people can benefit from creating their own private, idiosyncratic rituals. One woman who lost a spouse years ago told Norton, I washed his car every week as he used to do.

Theres no ancient text to say you should wash someones car, Norton says. But, by doing something personally relevant and symbolic, she felt better.

Share your money and time with others. Material purchases are less satisfying than buying experiences like taking a trip or attending a show, Nortons research shows. Even though vacations and restaurant outings may not be in the cards right now, we can still spend money in ways that foster shared experiences with loved ones.

For example, buying a ping-pong table, TV, or online movie subscription for the family to enjoy together might make you happier than purchasing a phone to use by yourself, he says.

Also, the research shows spending money on other people makes us happier than spending it on ourselves. Many are doing just that, donating a portion of their stimulus checks to food banks or to friends who are out of work. Some are helping others in non-financial ways, including recovered coronavirus patients donating plasma to help the sick.

During this crisis, you see people doing incredibly altruistic, kind, giving things, such as people getting food and medicine to the elderly neighbors theyve never met before, Norton says. When you give generously to others, it makes you happier than when you focus only on yourself.

Expressing gratitude also acts as a powerful source of well-being, increasing dopamine levels and boosting productivity, says Gino. Ive gotten into the habit of calling or writing a note to people I havent talked to in a while to express gratitude for something they have done, she says. Showing someone else appreciation makes us feel good.

While life might have seemed simpler and more predictable prior to the coronavirus invading our world, thats probably an illusion. A cluttered home will probably still be messy when the virus abates.

Don't romanticize what life was before the coronavirus, Schlesinger says. Your house wasnt perfect.

When Schlesinger checks in with his grown children, he reminds them that the COVID-19 pandemic will end. Eventually, people will return to work, whether at their old jobs or new positions. Children will go back to school and catch up on missed lessons. The economy will stabilize.

And then, Brooks says, we'll look back on this and say, Hey, remember when we were all home together?

Dina Gerdeman is senior writer at Harvard Business School Working Knowledge, and Danielle Kost is senior editor.

[Image: jeffbergen]

Share your insights below.

Originally posted here:
Fighting the COVID Blues: Advice from Business Research - Harvard Business School Working Knowledge

SAN FRANCISCO, May 19, 2020 /PRNewswire/ -- The global hormone replacement therapy marketsize is expected to reach USD 39.6 billion by 2027, expanding at a CAGR of 7.7%, according to a new report by Grand View Research, Inc. A significant rise in the incidence rate of hormonal disorders in the newborns, adults, and elderly and populations is driving the market. The Prader-Willi syndrome (PWS) affects one in every 15,000 newborns, thereby boosting the demand for the therapy.

Key suggestions from the report:

Read 100 page research report with ToC on "Hormone Replacement Therapy Market Size, Share & Trends Analysis Report By Product (Estrogen, Human Growth), By Route Of Administration (Oral, Parenteral), By Type Of Disease, By Region, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/hormone-replacement-therapy-market

Estrogen replacement hormone therapy helps in reducing the vaginal indications of menopause, such as dryness, burning, itching, and pain during intercourse. Estrogen is available in the forms of pill, gel, skin patch, cream or spray form. It is highly successful for treating problematic menopausal night sweats and hot flashes. Around 45% of women between the ages of 40 to 60 years of age were reported taking counseling sessions from a physician regarding the advantages and disadvantages of using hormone replacement therapy (HRT) after menopause.

Growing awareness about menopausal signs and the treatment options is growing the HRT market. Owing to the significant development for ERT, there has been an initiation of very safe treatment options for the patients situated in various geographies of the world. For example, augmentation of innovative drug delivery systems like transdermal estrogen patches and vaginal estrogen drugs.

Grand View Research has segmented the global hormone replacement therapy market based on product, route of administration, type of disease, and region:

Find more research reports on Pharmaceuticals Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: +1-415-349-0058Toll Free: 1-888-202-9519Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

See the original post:
Hormone Replacement Therapy Market Size Worth $39.6 Billion By 2027: Grand View Research, Inc. - P&T Community

Newtown May 18, 2020 (Thomson StreetEvents) -- Edited Transcript of Onconova Therapeutics Inc earnings conference call or presentation Thursday, May 14, 2020 at 8:30:00pm GMT

* Abraham N. Oler

Onconova Therapeutics, Inc. - Senior VP of Corporate Development & General Counsel

Onconova Therapeutics, Inc. - CFO

Onconova Therapeutics, Inc. - Chief Medical Officer and Senior VP of Research & Development

* Steven M. Fruchtman

Onconova Therapeutics, Inc. - CEO, President & Director

Laidlaw & Company (UK) Ltd., Research Division - MD of Healthcare Research & Senior Biotechnology Analyst

H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

Ladies and gentlemen, thank you for standby, and welcome to the Onconova Therapeutics First Quarter 2020 Earnings and Corporate Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Avi Oler, Senior Vice President, Corporate Development and General Counsel. Thank you, sir. Please go ahead.

Abraham N. Oler, Onconova Therapeutics, Inc. - Senior VP of Corporate Development & General Counsel [2]

Thank you, operator. Good afternoon and welcome to Onconova's First Quarter 2020 Corporate Update and Financial Results Conference Call. Earlier this afternoon, we issued a press release outlining our financial results and business progress during the quarter. If you have not seen this press release, it is available on the Investor Relations page of our website at http://www.onconova.com.

On today's call, Dr. Steve Fruchtman, President and CEO, will discuss the company's recent highlights and anticipated clinical and business milestones. After Steve completes his opening remarks, Mark Guerin, our Chief Financial Officer, will review first quarter financial results. Following Mark's report, we will move to the Q&A portion of the call, which will be joined by Dr. Rick Woodman, our Chief Medical Officer. Lastly, Steve will come back with some final comments and a review of our upcoming milestones.

Before we begin, I remind everyone that statements made today during this conference call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Onconova disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. Please see the forward-looking statements disclaimer in the press release issued this afternoon and the risk factors in the company's current and future filings with the SEC.

With that, it is my pleasure to now turn the call over to Steve.

Thank you, Avi. Good afternoon, everyone, and thank you for joining today's call. First, our hearts go out to the many individuals and families impacted by the devastating COVID-19 pandemic. The world has truly changed, and we hope that brilliant scientists from around the world can bring new therapies and preventions to this devastating plague.

Onconova demonstrated significant progress during the first quarter of 2020, highlighted by the completion of enrollment of our pivotal Phase III INSPIRE trial in higher-risk myelodysplastic syndromes. We are fortunate to have achieved full enrollment prior to the profound impact of the worldwide COVID-19 pandemic, which has forced disruptions to research studies at many hospitals and cancer centers across our globe.

With enrollment now completed, Onconova's pivotal Phase III INSPIRE trial is advancing to the next pivotal catalyst. Based on historical survival trends in the INSPIRE trial, we continue to anticipate reporting top line survival data in the second half of 2020. And we expect to present the results of the INSPIRE trial at a major medical meeting later this year. With INSPIRE enrollment now complete, we are preparing for when we reach 288 survival events before analyzing and releasing top line survival data.

To shorten time lines for our anticipated NDA submission to the FDA, we have already begun NDA work prior to data readout. We are working with regulatory consultancy experts on our NDA document for the U.S. FDA as well as on the MAA document for the EMA to be in position to expedite our health authority applications when data becomes available.

We are also advancing our plans to be ready for commercialization. And to develop internal Onconova expertise, we have nominated a commercial expert, Ms. Terri Shoemaker, to our Board, who was instrumental in the commercialization of azacitidine, the most frequently prescribed pharmaceutical agent in higher-risk MDS.

As you recall, INSPIRE is an open-label, randomized, controlled, international study designed to determine the efficacy, safety and tolerability of single-agent intravenous rigosertib in the treatment of patients with second-line, high-risk MDS. Patients in this study are less than 82 years of age and have progressed on, relapsed or failed to respond to previous treatment with the standard of care hypomethylating agent therapy. The study randomized patients to receive either intravenous rigosertib with best support of care or the physician's choice of therapy with best support of care.

The primary end point of this study is overall survival of all randomized patients in the intent-to-treat population. There is also a second opportunity for an FDA approval, which is the sequential analysis of the overall survival of the very high-risk subgroup as defined by the revised International Prognostic Scoring System. Should rigosertib prolong survival in the INSPIRE trial in a statistically significant manner, we believe rigosertib could be the first new treatment for higher-risk MDS in more than 15 years.

Today, we disclosed that at the European Hematologic Association's upcoming virtual congress, Onconova and our collaborators at MD Anderson Cancer Center and the centers participating on the INSPIRE trial have an accepted presentation. The presentation, which was just posted to the European Hematology Association's website, detail the impact of the RAS pathway mutations on patients failing azacitidine and is entitled, Mutations in RAS Pathway Genes Correlates with Type of Failure to Azacitidine: Genomic Analysis at Randomization onto the INSPIRE Trial.

As you know, advances in the understanding of genomics have revolutionized cancer care. Participants on the INSPIRE trial received deep genomic sequencing of their blood or bone marrow at randomization and at multiple time points in their treatment during the study. The genomic data from the INSPIRE trial identifies the most common mutations in high-risk MDS following azacitidine failure, including those of the RAS pathway that may be targeted by rigosertib. We believe this data presentation will further advance the learnings about MDS, the important role of genomics and the possible place of rigosertib treatment for MDS and other RAS-driven cancers.

We have made important progress with our additional pipeline programs as well. In addition to the INSPIRE trial, we are advancing plans for a pivotal Phase II/III combination trial of oral rigosertib and azacitidine in adult patients with HMA-naive, higher-risk MDS. We received feedback from the FDA in 2019 and are preparing a Phase II/III protocol for submission based on their guidance. We anticipate meeting with the FDA in the third quarter of this year after submitting a Type C meeting request to consult with FDA. We anticipate this new registration trial will begin later this year following the FDA feedback and following the survival pivotal data readout from our INSPIRE study.

We have also received notification that the Phase I trial, which forms the basis for this new pivotal trial with oral rigosertib combined with azacitidine in HMA-naive, high-risk MDS patients, has been accepted for publication in Leukemia Research and anticipate its publication in the upcoming months.

In addition to studying rigosertib in MDS, we are primed for additional rigosertib development progress, including the to be initiated Phase I/IIa study of rigosertib plus nivolumab in Stage 4 KRAS-mutated lung adenocarcinomas following the reopening of clinical cancer research programs post the COVID-mandated stoppage as well as additional planned indications for rigosertib in other KRAS-mutated cancers and our pipeline programs. The study in KRAS-mutated lung adenocarcinoma will be an investigator-sponsored trial, and we anticipate the first patient will be enrolled following the mitigation of the burden of the COVID pandemic that has been placed on our academic medical centers.

While checkpoint inhibitors represent a significant advancement in the standard of care in treating lung cancer and have achieved blockbuster status many times over, tremendous unmet medical need continues to exist following disease progression. In our view, this makes our novel combination approach with rigosertib a very attractive option to pursue in lung cancer and potentially beyond.

And beyond rigosertib, ON123300 is our investigational first-in-class dual inhibitor of CDK4/6 and ARK5. We believe ON123300 has the potential to treat numerous cancers, including refractory metastatic breast cancer, with CDK4/6 inhibitors already commercially available. For those who are not familiar with this field, CDK inhibitors have emerged as promising compounds targeting very large cancer indications such as hormone receptor-positive metastatic breast cancer. Due to its unique targeting of ARK5 as well as CDK4 and 6, we believe ON123300 has the potential to overcome many of the existing agents' limitations, making it potentially suitable for certain cancers that may not be responsive to the current generation of commercially available CDK4/6 inhibitors. If successful, we believe ON123300 could address this very large market opportunity.

We maintain global rights of ON123300 outside of China. Our partner in China for this compound is HanX Biopharmaceuticals, who funded the Chinese IND-enabling studies. The Chinese IND was approved in January of 2020 by the Chinese health authority. We anticipate a Phase I study may begin in China in the second half of 2020. We also intend for the Chinese IND-enabling studies to comply with our FDA standards. To the U.S. and the rest of the world outside of China, our manufacturer for ON123300 is now qualified. We plan to file a U.S. IND in the fourth quarter of 2020 after obtaining the required manufacturing data.

With regard to business development. During the first quarter, we reacquired rigosertib rights in Greater China. As a result, Onconova controls the rights for rigosertib in the U.S., Europe and China, which are among the largest pharmaceutical markets in the world. Last year, we announced plans to launch an early access program with Inceptua Medicines Group. We anticipate launching this program in select countries in the second half of this year. We expect to continue to evaluate opportunities as we progress from one milestone to the next milestone.

As a reminder, our upcoming Annual General Meeting of Stockholders is coming up on May 27. I encourage stockholders to vote at our upcoming Annual General Meeting. Our proxy materials are available on our website. I am very excited that Onconova's Board of Directors has nominated life science industry veteran, Terri Shoemaker, to join the Board at this time. As mentioned, Terri has highly relevant experience in the MDS space. Terri was a key executive in the launch of azacitidine in MDS and will be a very valuable addition to our Board of Directors. We believe her experience in developing and managing commercial organizations in the life science industry will be instrumental in our efforts moving forward as we prepare for potential commercialization of rigosertib.

And now I'd like to turn the call over to Mark Guerin, our Chief Financial Officer, for a discussion of our financial results for first quarter 2020. Mark?

--------------------------------------------------------------------------------

Mark Patrick Guerin, Onconova Therapeutics, Inc. - CFO [4]

--------------------------------------------------------------------------------

Thanks, Steve, and good afternoon, everyone. Cash and cash equivalents as of March 31, 2020, totaled $31 million compared to $22.7 million as of December 31, 2019. As previously noted, common stock warrant exercises since our financing transaction in November 2019 have added $10.6 million of cash to our balance sheet. Also, of the almost 29 million stock warrants outstanding as of March 31, 2020, over 80% of them were in-the-money as of May 13. Based on our current projections, we expect that our cash and cash equivalents will be sufficient to fund our ongoing trials and operations into the third quarter of 2021.

Our net loss was $5.1 million for the quarter ended March 31, 2020, compared to $7.6 million for the comparable period in 2019. Research and development expenses were $3.4 million for the quarter ended March 31, 2020, and $4.1 million for the comparable period in 2019. General and administrative expenses were $1.8 million for the quarter ended March 31, 2020, and $3.2 million for the comparable period in 2019.

This completes my financial review. I'll now turn the call back to Steve.

--------------------------------------------------------------------------------

Steven M. Fruchtman, Onconova Therapeutics, Inc. - CEO, President & Director [5]

--------------------------------------------------------------------------------

Thank you so much, Mark. With that, we'd like to open the call for questions. After the Q&A, I'll finish with some final closing remarks. Operator, please open the call to Q&A session, and thank you.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question comes from the line of Joe Pantginis with H.C. Wainwright.

--------------------------------------------------------------------------------

Joseph Pantginis, H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst [2]

--------------------------------------------------------------------------------

Glad you're all doing well. So I have 3 questions, 2 of which, I think, are pretty much logistical. The first one is with regard to INSPIRE, it's great that you enrolled everyone right now and things are progressing and the time lines are still on track. So I was just curious, as part of your -- I guess, call it, your statistical assumptions now with COVID, is there a potential for any loss to follow up for any of these patients that you might not hear about some of these events? Or is it not a concern?

--------------------------------------------------------------------------------

Steven M. Fruchtman, Onconova Therapeutics, Inc. - CEO, President & Director [3]

--------------------------------------------------------------------------------

I'll ask Rick to take that question, and thank you, Joe.

--------------------------------------------------------------------------------

Richard Charles Woodman, Onconova Therapeutics, Inc. - Chief Medical Officer and Senior VP of Research & Development [4]

--------------------------------------------------------------------------------

Yes, Joe. Thank you. The main challenge with the COVID pandemic for our global study has been monitoring of the sites. Fortunately, the number of patients in which we are not able to confirm survival events is extremely small. And we anticipate that continuing in part due to the efforts of our CRO and the clinical research assistance in the field and the team in Onconova as well as some good luck. And I think that we anticipate for the remainder of the collection of survival events that we will be able to continue doing that monitoring. But it is a challenge, and the monitors and the team have -- had to develop unique ways in which to interact with the sites because of the pandemic.

--------------------------------------------------------------------------------

Joseph Pantginis, H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst [5]

--------------------------------------------------------------------------------

Got it, Rick. And then my second logistical question, if you will. I know we discussed this in the past, but sometime has elapsed, and I just want to make sure if your thinking is still the same with regard to the communication strategy around putting out the data for INSPIRE. So since you're looking to present them at a major medical meeting in the second half, I'll just say presumably ASH, would you look to then have one of those typical top line press releases to say, okay, it hit, and we'll give the further data at an upcoming conference? Or not hit as...

--------------------------------------------------------------------------------

Steven M. Fruchtman, Onconova Therapeutics, Inc. - CEO, President & Director [6]

--------------------------------------------------------------------------------

Avi, why don't -- I'll ask Avi to take that one, if I may. Go ahead, Avi.

--------------------------------------------------------------------------------

Abraham N. Oler, Onconova Therapeutics, Inc. - Senior VP of Corporate Development & General Counsel [7]

--------------------------------------------------------------------------------

Sure. Sure thing. In terms of communication, Joe, thanks for the question, but you're exactly right that we would anticipate announcing the data when it is ready at a top line level and presenting full data at an upcoming major medical meeting such as ASH or another major medical meeting.

--------------------------------------------------------------------------------

Joseph Pantginis, H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst [8]

--------------------------------------------------------------------------------

Got it. And then my question is -- or my third and last question. With regard to the upcoming Type C meeting, obviously, you've already had a lot of productive discussions with the FDA around the study design. So I guess I would ask it 2 ways. What's your wish list of what you want to get out of there? And what are the key outstanding things that you need to get solidified?

--------------------------------------------------------------------------------

Steven M. Fruchtman, Onconova Therapeutics, Inc. - CEO, President & Director [9]

--------------------------------------------------------------------------------

Rick?

--------------------------------------------------------------------------------

Richard Charles Woodman, Onconova Therapeutics, Inc. - Chief Medical Officer and Senior VP of Research & Development [10]

--------------------------------------------------------------------------------

Yes, Joe. So I think the first part to your question is that we want to get agreement from the FDA on a novel, unique, adaptive design, a combination of a Phase II/III. And this adaptive design we presented at ASH and some of the unique features. We feel this design is particularly advantageous for us in a variety of ways as well as the medical community and the health authorities. And I think it is the additional challenge that we have is developing, particularly, as we indicated in the abstract at ASH, a very rigorous and robust interim analysis that allows us to move forward into the Phase III part of the study.

--------------------------------------------------------------------------------

Operator [11]

--------------------------------------------------------------------------------

Your next question comes from the line of Naureen Quibria with Maxim Group.

--------------------------------------------------------------------------------

Naureen Quibria, Maxim Group, LLC - Senior Equity Research Associate [12]

--------------------------------------------------------------------------------

So first, I guess, starting first with INSPIRE. Can you remind us or are you able to disclose what the current event rate is right now? And is there an average number of events that you're seeing per month? Are you able to discuss that in any detail?

--------------------------------------------------------------------------------

Steven M. Fruchtman, Onconova Therapeutics, Inc. - CEO, President & Director [13]

--------------------------------------------------------------------------------

I think I'll try my hand at that, and thank you very much. We did reveal, I believe mid-March, that we have over 85% of our survival events that we require of the 288. And the reality is it's quite variable. We do monitor by month every -- the survival events that we see, it is variable. But based on what we are observing, we anticipate reaching pivotal data the second half of 2020. So before the end of the year. It's harder -- it's very hard to make a more accurate prediction than that.

--------------------------------------------------------------------------------

Naureen Quibria, Maxim Group, LLC - Senior Equity Research Associate [14]

Original post:
Edited Transcript of ONTX earnings conference call or presentation 14-May-20 8:30pm GMT - Yahoo Finance

RALEIGH, N.C., May 21, 2020 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued two key patents related to its lead asset, Kyzatrex*. Kyzatrex is an oral Testosterone Replacement Therapy (TRT) that uses an innovative formulation to improve effectiveness and safety.

These allowed claims will provide strong IP protection to December 2030, over 8 years of potential commercial runway. They supplement Marius Pharmaceuticals already robust global patent portfolio for Kyzatrex, which includes granted patents in the European Union, Canada, China, Taiwan, Japan, New Zealand and other key markets, and pending applications in India, and US. Marius Pharmaceuticals patent portfolio includes filings that extend protection to 2033, with the potential to extend protection out to 2040.

The allowed claims protect Kyzatrex, an innovative formulation designed to increase bioavailability and provide a favorable pharmacokinetic (PK) profile compared to other therapeutic alternatives. Om Dhingra, Chief Executive Officer of Marius commented This innovation is truly exceptional as we have created a formulation with a unique PK profile which we believe drives important clinical significance.

Marius Pharmaceuticals Chief Financial Officer Shalin Shah said We are very pleased to strengthen the intellectual property portfolio for Kyzatrex and excited that it has tremendous potential to be differentiated and unique option in the TRT space. We are also drawing a line in the sand between a new treatment paradigm and old testosterone therapies.

Marius Pharmaceuticals has recently completed its pivotal Phase 3 study for Kyzatrex and intends to submit its New Drug Application (NDA) to the Food & Drug Administration (FDA).

About Kyzatrex

Kyzatrex is an experimental therapy for the treatment of primary and secondary hypogonadism (congenital or acquired). Testosterone is a crucial hormone that plays key roles in human growth and development and a wide range of other functions including metabolic and cardiovascular. Sources estimate that 15 million men in the United States suffer from hypogonadism, but only approximately 10% are currently treated. The co-morbidities of men suffering from hypogonadism are also a significant burden on patients and the healthcare system, these include Type 2 Diabetes and other serious chronic conditions.

Current marketed treatments are dominated by painful injections and messy topical applications with transference risk. Kyzatrex is an orally administered therapy, which avoids those drawbacks. Market research points to 93% of patients indicating they would ask their physician about Kyzatrex and more than half would consider a switch from their current regimen.

About Marius Pharmaceuticals

Marius pharmaceuticals is a cutting-edge biopharma company focusing on treating widespread conditions that have been triggered primarily through Androgen deficiency. Our pipeline consists of assets focused on inflammation while our commercial arm is at the forefront of data science technologies core to our commercialization of our lead asset Kyzatrex.

*Kyzatrex is a tentative Tradename currently under review with the FDA

For more information, contact:Shalin Shahshalin@mariuspharma.comwww.mariuspharma.com

Read the rest here:
Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy - Yahoo Finance

Analysis Report on Male Hypogonadism Market

A report on global Male Hypogonadism market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Male Hypogonadism Market.

Request Sample Report @https://www.mrrse.com/sample/15062?source=atm

Some key points of Male Hypogonadism Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Male Hypogonadism Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Male Hypogonadism Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Male Hypogonadism market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Male Hypogonadism market is analyzed and depicted in the report.

The global Male Hypogonadism market segment by manufacturers include

Competition Landscape

This analytical research report on the global male hypogonadism market is a complete package, which includes intelligence on key participants underpinning the market expansion. In the last chapter of the report, which elucidates the competitive scenario of the market, strategies implemented by the market players, along with their product overview, company overview, key financials, key developments and SWOT analysis has been rendered exhaustively. In addition, region-wide spread of these market players, their future expansion plans, market shares, revenues, and mergers & acquisition activities between them have been described in detail in this concluding chapter of the report. An intensity map has been employed in the report to profile the market players situated across geographies.

Research Methodology

Credibility of the researched statistics and data is backed by the unique research methodology employed by the analysts at PMR, which ensures higher accuracy. PMRs research report on the global male hypogonadism market can assist its readers in gaining detailed insights on many different aspects governing the market around key regional segments included in the report. The report readers can further slate key strategies for tapping into vital revenue pockets and gaining benefits over the intensifying competition in the market. Information presented in the report has been scrutinized and monitored thoroughly by PMRs industry experts. Figures and numbers offered in the report have also been validated by the analysts in order to facilitate strategic decision making for the report readers.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/15062?source=atm

Important queries addressed in the report:

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Male Hypogonadism economic market. This included the CAGR value during the outlook period leading to 2025.

Buy This Report @ https://www.mrrse.com/checkout/15062?source=atm

Benefits of Purchasing Male Hypogonadism Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read the rest here:
The Economic Impact of Coronavirus on Male Hypogonadism Market Analysis and Value Forecast Snapshot by End-use Industry 2019-2021 - 3rd Watch News

Breakthrough genome editing companies includingEditas (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) have been in a tailspin since late 2019, and the latest earnings reports from both of those companies show that their revenue from collaborations and partnerships has started to dry up despite positive revenue growth overall.

Both companies aim to produce gene therapies utilizing CRISPR-based genetic editing in living patients, though their methods of delivering that therapy differ substantially. Neither company has a product on the market, though Editas beat Intellia to clinical trialsin April when it began testing EDIT-101 for Leber congenital amaurosis, a type of congenital blindness. Nonetheless, Editas is many years away from its first therapy being approved for sale, assuming that EDIT-101 proceeds past phase 1.

Investors considering either of these two companies should be aware that both are risky choices with no guarantee of a payoff over any term. There is one significant difference that wise investors will weigh carefully, however: Editas's partnerships and strategic collaborations appear positioned to be far more fruitful for the company than Intellia's.

Image source: Getty Images.

Intellia is a slightly smaller company than Editas, but its pipeline is comparable in breadth. The companies are of similar age, with Editas having been founded in 2013 and Intellia in 2014. However, Intellia's network of collaborations and research partnerships is far less lucrative, and its pipeline projects may soon require new funding to move forward.

Intellia's partners include pharma giantNovartis (NYSE:NVS) and biotechRegeneron (NASDAQ:REGN). Novartis made a substantial equity investment in Intellia as part of that partnership, and Novartis also retained exclusive rights to develop any engineered CAR-T cancer therapies produced by the collaboration. Intellia also agreed to give Regeneron the exclusive right to develop CRISPR-based therapies targeted at any of 10 different genes in the liver.

The terms of these collaborations make Intellia unable to capitalize on major successes beyond extending the depth of integration with its partners. Thus, in the long view, the company's path forward would still require moving its wholly owned therapy candidates to market, even if its approach is proven by a collaborator's success.

Editas's partnerships, on the other hand, are substantially more equitable. Editas's major drug development collaborations include Allergan (now part of AbbVie (NYSE:ABBV) and biopharma giantBristol Myers Squibb (NYSE:BMY). The expectation with these collaborations is that the more mature partner companies will be responsible for clinical-stage development, with Editas providing trial-ready therapy candidates and a technology platform to develop similar therapies according to the partners' needs.

Should these candidates show promise in phase 2 clinical trials investigating preliminary efficacy, the company's collaborators would likely respond by initiating new collaborations to capitalize on Editas's platform before its output is replicated by a competitor like Intellia. But Editas isn't in the same position as Intellia with regard to its major collaborations because it has a chance to capture the upside of collaborators' successes as well.

Editas's collaboration with Allergan specifies that both parties have optionality to co-develop any successful programs, and that Editas will share the revenue and losses of those programs equally with Allergan.And Editas's previous collaborations with companies like Celgene demonstrate that companies collaborating with Editas do so to access its gene-editing platform as customers as much as partners.

Editas also has partnerships with research-stage small preclinical companies such as Sandhill Therapeutics. Sandhill's therapeutic platform could benefit immensely from integrating Editas' genetic editing technologies. A similar research-stage pact with BlueRock Therapeutics initiated in 2019 has already advanced to clinical pipeline collaborations for Editas, proving that working with external peers is one of the company's organizational strengths.

It's important to remember that Editas's collaboration advantage is far from the only ingredient the company needs to survive in the medium term. Reliable revenue remains absent, and collaborations are vulnerable to amendment if the company can't deliver what its collaborators need to move products through the clinical trial process.

Data by YCharts

For the moment, neither Editas nor Intellia warrants a definite buy, and present holders of Intellia may want to consider selling. If Intellia cancels any of its preclinical programs, consider it a strong sign that the company's health is deteriorating. Look at Editas's performance in the second and third quarters to see if they're on the right track for a buy early next year, but understand that waiting until next year to reevaluate the company's situation is probably the wisest path.

View post:
Here's Why Editas Could Beat Intellia to a CRISPR Therapy - Motley Fool

A desperately needed tool to curb the COVID-19 pandemic is an inexpensive home-based rapid testing kit that can detect the coronavirus without needing to go to the hospital.

The Food and Drug Administration has approved a few home sample collection kits but a number of researchers, including myself, are using the gene-editing technique known as CRISPR to make home tests. If they work, these tests could be very accurate and give people an answer in about an hour.

I am a biomolecular scientist with training in pharmaceutical sciences and biomedical engineering and my lab focuses on developing next-generation of technologies for detecting and treating cancer, genetic and infectious diseases.

The COVID-19 disease is caused by a coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unlike humans which carry their genetic material encoded in DNA, the coronavirus encodes theirs in a related molecule called RNA.

My research group recently engineered a sensitive CRISPR-based technology, that we named CRISPR-ENHANCE, and used it to create a rapid test for SARS-CoV-2 RNA. Our assay works like a pregnancy test and shows two purple colored lines if the sample is positive for the virus. Using our technology, I envision developing a test kit that would allow rapid detection of SARS-CoV-2 RNA in saliva within 45-60 minutes at home without needing any expensive equipment.

The FDA recently gave a green light to a couple of sample collection kits from LabCorp and Everywell under the Emergency Use Authorization (EUA) that would allow people to ship out the nasal swab samples for analysis. Patients can take a swab of their nose, ship the samples to a lab, and wait for a few days to get the results back.

Although not an at-home testing kit, the test allows the samples to be shipped directly to a lab for detecting SARS-CoV-2 RNA. There they use a technique called reverse transcription-polymerase chain reaction (RT-PCR), which converts the viral RNA into DNA so that it can be easily multiplied and detected.

Although most FDA-approved tests are based on detecting SARS-CoV-2 RNA at an early stage, before symptoms even appear, such tests can only be performed in a laboratory setting with expensive equipment and can take multiple days to get the results.

Several antibody testing kits have been approved by the FDA that use a paper-based lateral flow strip, also similar to an at-home pregnancy testing strip, for detecting antibodies called IgM and IgG. Almost all SARS-CoV-2 infected patients make antibodies within 19 days of onset of symptoms and then the body continues to make detectable antibodies for several weeks to months even after symptoms fades away. Therefore, the Centers for Disease Control and Prevention recommends using antibody tests for detecting past infections.

However, the coronavirus is usually very active and contagious in the first week of infection and peaks on the day of onset of symptoms. Therefore, to prevent the spread of coronavirus, it is extremely important to detect coronavirus early to block the spread.

The antibody testing can be great for detecting past infections but they cannot reliably detect current or early infections. The delayed appearance and patient-to-patient variability of antibodies in a blood test further complicates the COVID-19 diagnosis with antibody testing kits.

In addition, the variability between different antibody testing methods have raised doubts about the reliability of these test kits.

Therefore, the National Institutes of Health recently announced a Rapid Acceleration of Diagnostics (RADx) which offers up to US$500 million in funding for ramping up the technologies that detect the SARS-CoV-2 virus.

Most people know of CRISPR/Cas systems as a famous gene-editing technology that can precisely edit DNA. Researchers engineer a guide RNA molecule with a target genetic sequence that serves like a GPS and zooms in on a location on the DNA where a Cas protein, a pair of molecular scissors, can cut at the desired location.

Scientists in the labs of Feng Zhang at MIT, Jennifer Doudna at UC Berkeley and others discovered several newer versions of CRISPR/Cas systems, including ones using the proteins Cas12a and Cas13a-d, which get crazy cutting once they find their match.

My colleagues and I have used this Cas12a-based CRISPR technique to detect the coronavirus.

The coronavirus RNA activates CRISPR/Cas, transforming a pair of controlled molecular scissors into an unstoppable chainsaw. When the the CRISPR/Cas enzyme activates, we know that the genetic sequence of the coronavirus is present in the saliva sample. To make the signal of the coronavirus stronger in the testing kit, we add millions of synthetic reporter molecules which are also chopped up by the CRISPR/Cas mechanism. This means that within minutes we can detect detect the presence of coronavirus.

Under EAU, the FDA recently approved the first CRISPR-based SARS-CoV-2 RNA testing kit from Sherlock Biosciences for testing nasal swabs in a lab. Although not yet approved for at-home testing, this is a big leap toward the development of CRISPR-based diagnostics.

While similar CRISPR-based test kits are in development including one from Mammoth Biosciences and others, our CRISPR-ENHANCE technology relies on engineered CRISPR RNAs that increases the speed of Cas12a chainsaw by between three- and four-fold.

This technique dramatically enhances the sensitivity of detection. Our system can detect fewer virus in a clinical sample faster with a clear visual readout. We are in the process of clinically validating the CRISPR-ENHANCE technology for SARS-CoV-2 RNA detection.

Standard collection method for detecting respiratory viruses in the clinic is the nasal swab. However, coronaviruses have been detected at comparable levels in saliva so some researchers are now turning to saliva for diagnostic testing.

Collecting saliva is not only less invasive than the nasal swabs but also contains more virus, which makes it easier to detect with RT-PCR. In fact, an at-home saliva collection kit just received a green light by the FDA on May 8, 2020. In our validation study we will be internally comparing our test between the nasal swabs and saliva for FDA approval.

We are developing a six-step procedure for home-based testing for saliva along with the nasal swabs. Here is how it would work with saliva.

Spit into a sample collection tube that contains dry chemical reagents that will begin to react with your saliva when you drop the closed tube into the warm water for 30 minutes.

The heat helps the chemicals break up the virus particle and expose the viruss genetic material RNA. The RT-PCR reagents basically multiply the viral RNA creating billions of copies, which are more easily detected.

After 30 minutes, transfer the contents of the collection tube to a second tube containing dried CRISPR components and leave it at room temperature for 10-15 minutes.

Only if CRISPR/Cas finds the specific coronavirus RNA, will it become active and chop up the synthetic reporter molecules that are engineered and added to this second tube. This part happens in just six minutes.

We then drop a paper strip into the second tube. Within 30 seconds one or two purple bands reveal the results.

The health care provider can then direct the individual to either quarantine, isolate and/or recommend further testing such as antibody-based tests. In our study, currently under peer review, we demonstrated that the ENHANCE technology itself is versatile and can also be adopted for detecting a range of targets including HIV, HCV and prostate cancer.

While there are several labs and companies are rushing to develop similar CRISPR-based coronavirus detection kits for saliva testing, we believe our approach offers the fastest detection. We hope to bring the cost of the kit down to between $1 and $2 so that developing countries can also afford a rapid and reliable coronavirus testing kit.

[You need to understand the coronavirus pandemic, and we can help. Read The Conversations newsletter.]

Read this article:
Rapid home-based coronavirus tests are coming together in research labs were working on analyzing spit using advanced CRISPR gene editing techniques...

On May 18, 2020, the Patent Trial and Appeal Board (PTAB) heard argument in Interference No. 106,115,University of California1v. Broad Institute2. The interference involves 10 patent applications of University of California (UC), and 13 patents and one patent application of Broad Institute (Broad), all of which have claims covering CRISPR-Cas9 technology in eukaryotic cells. The hearing took place before a panel of three administrative patent judges, Judge Katz, Judge Lane, and Judge Moore.

A patent interference is a proceeding formerly used to determine who first invented a claimed invention. Interferences were phased out in 2012 legislation, but patents or applications effectively pending before March 2013 still can be subject to an interference.

In January 2017, the PTAB declared a first interference between Broad and UC to determine which party was the first to invent the CRISPR-Cas9 technology. Instead of holding either party as prevailing, the PTAB determined there was no interference-in-fact, because Broad's invention, directed to CRISPR-Cas9 in eukaryotic cells, would not have been obvious from UC's invention, which claims the CRISPR-Cas9 system generically. Hence, the parties' patent claims were not directed to the same invention. The decision was upheld by the Federal Circuit in April 2018.

Shortly after the PTAB decision in the first interference, UC filed patent applications with claims directed to CRISPR-Cas9 system in eukaryotic cells. The newly filed UC claims cover essentially the same scope as Broad's claims that survived the first interference.3The patent examiner decided these claims were otherwise in condition for allowance except for a potential interference with Broad's claims. Subsequently, the PTAB declared the current interference on June 24, 2019.

Typically, one of the parties in an interference is deemed the "senior party," which means the party is entitled to the presumption that it is the prior inventor to make the earliest constructive reduction to practice. Any other party would be a "junior party." Curiously, neither Broad nor UC was accorded the benefit of the priority date of their first provisional application. Rather, both parties were accorded the date of the non-provisional applications involved in the interference, which made Broad the senior party based on dates of their non-provisional applications. Both parties have submitted motions and exhibits to support arguments for the benefit of an earlier priority date, and arguments against the other party's benefit. Most other motions have been deferred until a decision on the issues argued before the PTAB on May 18.

The arguments on May 18, 2020 mainly involved three issues: 1) whether the current interference should be barred by the PTAB's decision in the first interference as affirmed by the Federal Circuit; 2) whether UC should be accorded benefit of the date of its first provisional application (P1); and 3) whether Broad's motion for a different count should be granted.

Regarding the first issue, Broad took the position that the current interference should be barred under the doctrine known as estoppel. Essentially, Broad contended that the current interference proceeding should not have taken place, because the same issues based on same facts were already litigated in the first interference. In rebuttal, UC argued that the legal issue, i.e., whether UC's P1 would have sufficiently enabled a skilled person to use CRISPR-Cas9 in eukaryotic cells, was never litigated or decided.

The first and the second issues are more or less related. According to Broad, even though UC's P1 was not litigated in the first interference, it contained no new facts or experiments other than a laundry list of routine techniques. Broad also pointed to UC's own scientists' frustration and difficulties with CRISPR in eukaryotic cells, which they successfully relied on in the first interference. In response, UC maintained that P1 enclosed all necessary and sufficient components to use CRISPR-Cas9 in eukaryotic cells, because one would only need ordinarily known techniques to make the eukaryotic application. Judge Katz asked if there was anything special about one of the technologies (microinjection in zebrafish embryo, in particular) that UC argued as readily available at the time of P1, but didn't get a clear answer.

The third issue relates to a patent "count." At an early stage of an interference, the PTAB would determine a count, which defines the scope of the proofs for priority. The losing party of an interference would not be entitled to claims patentably indistinct from the count. In the current interference, the original count was directed to a eukaryotic cell comprising CRISPR-Cas9 system with a single guide RNA. Broad has submitted motions for a count that is not limited to single guide RNA only, but covers both single and dual guide RNAs. When UC argued that Broad should be held to the single guide RNA count it originally proposed, Judge Katz questioned the consistency of claim interpretation, as some of Broad's claims would fall out of the scope of the current count.

We expect the PTAB to issue a decision on the above discussed motions in the next one-to-three months. A decision for Broad on estoppel should result in a quick final judgment: the current interference proceeding will then be terminated. If the PTAB decides for UC with accorded benefit of priority, the interference will be redeclared, with UC as the senior party. If either party ends up with a significantly earlier accorded benefit date, the other party might face an order to show cause from the judges, because it would have to prove a massive amount of diligence to get behind the other party's benefit. The PTAB may also decide to change the count based on Broad's claims, or designate certain Broad claims as not corresponding to the count.

If the PTAB makes any decision other than a final judgment or an order to show cause, the parties will likely proceed to a phase where priority is determined, and where the deferred substantive motions may be argued and decided, for example, the parties' motions on patentability and inequitable conduct. Given the history of the patents and applications involved, this next phase could be quite complex and expensive for both parties.

[1] The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier, collectively referred to as UC.

[2]The Broad Institute, Inc., Massachusetts Institute of Technology, and Presidents and Fellows of Harvard College, collectively referred to as Broad.

[3] See, for example, U.S. Patent Application No. 15/981,807, claim 156.

View post:
Patent Trial and Appeal Board Hears Argument in CRISPR Patent Priority Dispute - JD Supra

Researchers are racing against time to find ways to treat and prevent COVID-19. There is currently no treatment for the disease, and the World Health Organisation has created Solidarity, a global clinical trial which is testing four drugs as possible treatment. There are also more than 90 vaccine trials being undertaken worldwide, but it may take more than a year before a vaccine is developed. And there is currently a global shortage of COVID-19 testing kits.

One of the methods researchers are exploring to combat COVID-19 is gene editing. Gene editing could potentially be used on the genome of the virus that causes COVID-19, to make it harmless. It could be used to develop better testing kits, and could even be used to edit the human genome to prevent people from being infected by the virus.

But gene editing is associated with a range of ethical issues such as safety, equal access and consent. Bioethicists and researchers believe that gene editing in humans must be proven to be safe before it can be offered as a treatment option. There is also the issue of equal access to treatment, which must be considered.

To ensure that an ethical approach to research for a cure for COVID-19 is taken, the International Bioethics Committee and the World Commission on the Ethics of Scientific Knowledge and Technology issued a joint statement calling for an interdisciplinary dialogue among scientific, ethical and political stakeholders. The joint statement does not describe specific treatment options, but it calls on the research community to work together to find a cure using a bioethics and ethics of science and technology perspective which is rooted in human rights.

Scientists have considered the possibility of CRISPR (or clustered regularly interspaced short palindromic repeats) technology being used to address the COVID-19 pandemic. CRISPR is a mechanism that arose in bacteria millions of years ago to fight off disease. The CRISPR protein can be used to target specific sequences of DNA, which it then cuts like a pair of scissors. The cut DNA strand can then repair itself, or a new DNA sequence can be inserted. It has now been turned into a biological tool for editing genomes of biological organisms in order to modify them or target disease. It therefore has a number of different uses, from improving crop quality to correcting genetic conditions.

There are three potential ways that CRISPR may help fight COVID-19:

CRISPR has the potential to disable the virus that causes COVID-19 by editing its genome so that it is, in effect, made harmless. Using an approach called PAC-MAN (Prophylactic Antiviral Crispr in huMAN cells), researchers at Stanford University have shown that CRISPR has the ability to attack the SARS-CoV-2 genetic makeup and reduce the amount of virus in a test solution by 90%. Research is ongoing, but its thought that this approach is so effective, it might have the potential to stop the disease in people. There would be no barrier to this research as long as researchers abide by the ethical and legal guidelines that apply to their institution and country.

Gene editing tools have the potential to improve testing rates and could be an answer to the global shortage of COVID-19 tests. Apart from being a gene editing tool, CRISPR is also a diagnostic tool, and can be used to detect infection in cells. Scientists are hopeful that CRISPR based testing will alleviate the global testing burden. While many of these tests are still in the development stage, the Food and Drug Administration approved a CRISPR-based COVID-19 diagnostic test by a Cambridge biotech start-up on 8 May 2020. The test can provide results within an hour, and the company making it claims that more than 1 million tests can be performed in a week. In order for these tests to be legally made available for use, they would need to be approved by the appropriate regulatory authority, such as the Food and Drug Administration in the US, or South Africas Health Products Regulatory Authority.

CRISPR creates the potential to edit peoples genes to make them resistant to infection. So, if we cant stop the virus, can we stop ourselves from getting infected? Gene editing in humans takes one of two forms: somatic cell editing and germline editing.

Somatic cell editing affects a persons body cells, while germline editing involves editing the DNA in sperm, eggs or embryos, resulting in genetic changes in an individuals descendants. There are a number of somatic cell CRISPR clinical trials being undertaken and some treatments have been successful. But germline editing is more controversial and over 40 countries prohibit it in their law.

When the Chinese scientist He Jiankui used CRISPR to edit the genomes of two children, he was criticised as acting unethically, since the safety and efficacy of germline editing has not been established. Scientists around the world called for a five-year moratorium on it. He Jiankui was sentenced to three years in prison in 2019.

There are also laws which will obstruct this potential use of CRISPR. Article 3 of the Oviedo Convention states that an intervention seeking to modify the human genome may only be undertaken for preventive, diagnostic, or therapeutic purposes and only if its aim is not to introduce any modification in the genome of any descendants. This has been interpreted as expressly forbidding germline gene editing.

National law can also prohibit this. Section 57 of South Africas National Health Act states that a person may not manipulate any genetic material, including genetic material of human gametes, zygotes or embryos. Section 57 is enacted to prohibit human reproductive cloning. But this law was enacted before CRISPR even existed and it mimics the approach taken in international law against genetic manipulation of gametes and embryos. There are licensed somatic cell CRISPR therapies available. But there are potential legal barriers to the lasting protection which germline CRISPR intervention would give us.

There is pressure on researchers to develop safe and effective treatment and vaccines. CRISPR technology has been used in a variety of ways, but it raises a series of ethical and legal issues with regard to its potential use in humans.

So far, scientists have been cautious about putting CRISPR technology to use in humans. But should CRISPR be considered as a legitimate weapon in the fight against the pandemic, knowing that time is of the essence? While we all act together in the fight against COVID-19, it cannot be at the expense of ethical and legal standards.

Continue reading here:
COVID-19 and gene editing: ethical and legal considerations - The Conversation Africa

DUBLIN--(BUSINESS WIRE)--The "Global Genome Editing Market By Technique (CRISPR, Zinc Finger Nucleases, TALENs, Restriction enzymes, Others), By Applications (Synthetic Biology, Engineering Cell Line and Organisms, Others), By Source, By End-User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Genome Editing Market is expected to grow at a brisk rate during the forecast period owing to growing number of research activities for treatment of various chronic diseases using this technology. Further, increased government funding for genomics technology around the globe, growing preference for personalized medicine and increase in R&D expenditure are fueling the market growth of genome editing.

Genome editing is a way of making specific changes to the DNA of a cell or organism. It could be used to edit the genome of any organism. It uses a type of enzyme called an engineered nuclease' which cuts the genome in a specific place. After cutting the DNA in a specific place, the cell naturally repairs the cut. It finds application in large number of areas, such as mutation, therapeutics, and agriculture biotechnology. Moreover, rise in the number of chronic and infectious diseases is likely to fuel the market for genome editing in the coming years.

The Global Genome Editing market is segmented based on technique, applications, source, end-user and region. Based on applications, the market is segmented into synthetic biology, engineering cell line & organisms, therapeutic genome editing and others. Among them, the cell line engineering is expected to witness the highest growth rate in the coming years due to increase in the number of people suffering with genetic disorders and rising government funding for stem cell research.

Based on end-user, the Global Genome Editing Market is segmented into pharmaceutical & biotechnology companies, clinical research organization and research institutes. Pharmaceutical & biotechnology companies contribute to the largest share of revenue generation for the Global Genome Editing Market. Growing establishments of biotech and pharma companies in emerging economies and growing usage of gene editing technique in research activities undertaken by them to manufacture and develop drugs for rare diseases anticipated to fuel the market across the globe.

Companies Mentioned

Objective of the Study:

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Global Genome Editing Market Outlook

4.1. Market Size & Forecast

4.2. Market Share & Forecast

4.3. Market Attractiveness Index

5. Asia-Pacific Genome Editing Market Outlook

5.1. Market Size & Forecast

5.2. Market Share & Forecast

5.3. Market Attractiveness Index

5.4. Asia-Pacific: Country Analysis

6. Europe Genome Editing Market Outlook

6.1. Market Size & Forecast

6.2. Market Share & Forecast

6.3. Market Attractiveness Index

6.4. Europe: Country Analysis

7. North America Genome Editing Market Outlook

7.1. Market Size & Forecast

7.2. Market Share & Forecast

7.3. Market Attractiveness Index

7.4. North America: Country Analysis

8. South America Genome Editing Market Outlook

8.1. Market Size & Forecast

8.2. Market Share & Forecast

8.3. Market Attractiveness Index

8.4. South America: Country Analysis

9. Middle East and Africa Genome Editing Market Outlook

9.1. Market Size & Forecast

9.2. Market Share & Forecast

9.3. Market Attractiveness Index

9.4. MEA: Country Analysis

10. Market Dynamics

10.1. Drivers

10.2. Challenges

11. Market Trends & Developments

12. Competitive Landscape

12.1. Competition Outlook

12.2. Players Profiled (Leading Companies)

13. Strategic Recommendations

14. About Us & Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/tgb83z

Read the original:
Outlook on the Worldwide Genome Editing Industry to 2025 - Featuring Pfizer, Bayer Crop Science & Editas Medicine Among Others -...

Global CRISPR Technology Market 2020 offers detailed research and analysis of the COVID-19 impact provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global CRISPR Technology market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global CRISPR Technology market is carefully analyzed and researched about by the market analysts.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/05212028897/COVID-19-Impact-on-CRISPR-Technology-Market-Global-Research-Reports-2020-2021/inquiry?source=coleofduty&Mode=48

Top Companies in the Global CRISPR Technology Market: Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT), Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, New England Biolabs, Origene Technologies, Synthego Corporation, Toolgen

CRISPR technology is a relatively new technology used in genome editing or gene editing; CRISPR-CAS-9 is a palindromic repeats cluster and is found naturally in bacteria. This sequence allows the bacteria to protect them from the virus by producing segments enzyme that cuts RNA or DNA virus and inactivate the virus. This ability of the CRISPR-CAS9 has allowed scientists to make DNA and RNA library as needed and their applications. CRISPR-CAS9 technology has potential applications in treating human disease, creating a gene library, and manipulate cell functions such as metabolism.

Market Segmented by Types:

Enzymes

Kits

gRNA

Libraries

Design Tools

Market Segmented by Applications:

Biomedical

Agricultural

Inquire for Discount:

https://www.marketinsightsreports.com/reports/05212028897/COVID-19-Impact-on-CRISPR-Technology-Market-Global-Research-Reports-2020-2021/discount?source=coleofduty&Mode=48

Regional Analysis:

For comprehensive understanding of market dynamics, the global CRISPR Technology Market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview of Market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

Take a look at some of the important sections of the report:

Market Overview:It starts with product overview and scope of the global CRISPR Technology market and later gives consumption and production growth rate comparisons by application and product respectively. In addition, it provides statistics related to market size, revenue, and production.

Production Market Share by Region:Apart from the production share of regional markets analyzed in the report, readers are informed about their gross margin, price, revenue, and production growth rate here.

Company Profiles and Key Figures:Each company profiling of leading players operating in the market growth keeping in view vital factors markets served, production sites, price, gross margin, revenue, production, product application, product specification, production sites and product introduction.

Manufacturing Cost Analysis: Readers are provided with detailed manufacturing process analysis, industrial chain analysis, manufacturing cost structure analysis, and raw materials analysis.

Market Dynamics:The analysts explore critical influence factors, market drivers, challenges, risk factors, opportunities, and market trends.

Browse for report description and TOC:

https://www.marketinsightsreports.com/reports/05212028897/COVID-19-Impact-on-CRISPR-Technology-Market-Global-Research-Reports-2020-2021?source=coleofduty&Mode=48

Finally, CRISPR Technology Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

We Also Offer Customization on report based on specific client Requirement:

Free country Level analysis for any 5 countries of your choice.

Free Competitive analysis of any 5 key market players.

Free 40 analyst hours to cover any other data point.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

See original here:
CRISPR Technology Market Technology Advancements, Overview and Developments in Medical Industry 2020 to 2021 - Cole of Duty

The global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market. The Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2636510&source=atm

The key players covered in this studyThermo Fisher ScientificMerckGenScriptIntegrated DNA TechnologiesHorizon Discovery GroupAgilent TechnologiesCellectaGeneCopoeiaNew England BiolabsOrigene TechnologiesSynthego CorporationToolgen

Market segment by Type, the product can be split intoProductsServicesMarket segment by Application, split intoBiomedical ApplicationsAgricultural ApplicationsIndustrial ApplicationsBiological Research

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology status, future forecast, growth opportunity, key market and key players.To present the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2636510&source=atm

The Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market research covers an exhaustive analysis of the following data:

The Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market research addresses critical questions, such as

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2636510&licType=S&source=atm

The global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

Here is the original post:
COVID-19: Potential impact on Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market by Application Analysis 2019-2029 -...

The Smithsonians National Zoo and Conservation Biology Institute is asking the public to help name the litter of four cheetah cubs born April 8 at the Smithsonian Conservation Biology Institute (SCBI) in Front Royal, Virginia. The births were streamed live on the Zoos new cheetah webcam, and virtual viewers have been watching them grow ever since. Keepers currently identify each cub by a small shave mark on their left shoulder (male), right hip (female), left hip (male) and base of the tail (male). Voters can select their favorite names from May 22 to May 26on the Zoos website.

The names were selected from a list submitted to SCBIs cheetah animal care team by staff from across the Zoo, SCBI and Friends of the National Zoo (FONZ), the Zoos membership organization. There are three possible name choices for the female cub and five choices for the three male cubs. The names that receive the most votes will be bestowed on the cubs. Keepers will assign the winning names to the individual animals. The winning names will be announced May 27.

The name choices for the female cub are:

The name choices for the three male cubs are:

The cubs were born to first-time mom, 5-year-old Echo and sired by 4-year-old Scott. Staff have been closely monitoring Echo and her cubs via the webcam. Keepers approached the cubs for the first time April 14. Less than a week later, the cubs were sexed and weighed. The cubs had their first vet exam May 20. Follow #CheetahCubdates on the Zoos Facebook, Instagram and Twitter to stay up-to-date on cheetah cub milestones.

The cheetah webcam is one of six live animal webcams hosted on the Zoos website. A downloadable animal webcam educational activity packet is available. As the cheetah cubs continue to grow, they will spend more time outside the den. If the cubs are not on the cam,the public can check out the photos and videos located on the cams page.

SCBI is part of the Cheetah Breeding Center Coalitiona group of 10 cheetah breeding centers across the United States that aim to create and maintain a sustainable North American cheetah population under human care. These cubs are a significant addition to the Association of Zoos and Aquariums Species Survival Plan for Cheetahs, as each individual contributes to this program. Earlier this year, SCBI experts performed a successful in vitro fertilization resulting in two cubs.

Cheetahs live in small, isolated populations mostly in sub-Saharan Africa. Many of their strongholds are in eastern and southern African parks. Due to human conflict, poaching and habitat- and prey-base loss, there are only an estimated 7,500 to 10,000 cheetahs left in the wild. TheInternational Union for Conservation of Natureconsiders cheetahsvulnerableto extinction.

As a public health precaution due to COVID-19, the Smithsonians National Zoo and Conservation Biology Institute is temporarily closed to the public. Animal keepers and veterinary staff remain working on site at the Zoo and SCBI to provide the usual highest quality care for the animals.Due to the public closure, a COVID-19 Emergency Fund has been created as the Zoo is no longer receiving important funds on which it relies.Additional information on the Zoos COVID-19 response is posted to theZoos website. During the closure, the Zoo is sharing animal updates from behind the scenes using the hashtag #NatZooZen onFacebook,InstagramandTwitter.

The Zoos legacy of conservation work extends beyond the public Zoo in Washington, D.C., to SCBI in Front Royal, Virginia. Scientists at SCBI study and breed more than 20 species, including some that were once extinct in the wild, such as black-footed ferrets and scimitar-horned oryx. Animals thrive in specialized barns and building complexes spread over more than 3,200 acres. The sprawling environment allows for unique studies that contribute to the survival of threatened, difficult-to-breed species with distinct needs, especially those requiring large areas, natural group sizes and minimal public disturbance.

SCBI spearheads research programs at its headquarters in Virginia, the Zoo in Washington, D.C., and at field research stations and training sites worldwide. SCBI scientists tackle some of todays most complex conservation challenges by applying and sharing what they learn about animal behavior and reproduction, ecology, genetics, migration and conservation sustainability.

Read more here:
Smithsonian's National Zoo Seeks Help in Naming Four Cheetah Cubs - Smithsonian's National Zoo and Conservation Biology Institute

The difference in COVID-19 death rates between white people and black, Asian and minority ethnic (BAME) people in the UK is shocking. One recent report found that, between the beginning of February and the end of April 2020, black people in England were 71% more likely than white people to die from COVID-19. And Asian people were 62% more likely.

This disparity has led to an inquiry by Public Health England and funding for urgent academic research into the issue. We expect many factors to be involved, including the disadvantages that BAME people face due to greater chances of poverty and health issues.

But its important that we examine whether there may also be a genetic component to the problem in order to fully understand whats going on. My colleagues and I are conducting research among frontline healthcare workers to try to see if there are any innate differences in the way different peoples immune systems respond to this specific virus, including genetic differences that may be associated with ethnicity.

Researchers have identified a greater chance of dying from COVID-19 among BAME people in several countries aside from the UK, including Norway and the US. There are many social reasons why ethnic minorities may generally be more vulnerable to disease, including a greater chance of malnutrition, more exposure to pollution due to where they live, or greater likelihood of working in less healthy environments.

Inequality and poverty also play a role in the fact that BAME people are more likely to suffer conditions that we know are linked to a greater chance of dying from COVID-19, such as diabetes and heart disease.

Initial data suggests that BAME healthcare workers are more likely to die from COVID-19 than their white colleagues. British Medical Association research has found that BAME doctors are twice as likely as white doctors to feel pressured into working with inadequate PPE when they are at risk of infection. And they are twice as likely not to feel confident enough to raise concerns about workplace safety.

However, all these established facts alone dont seem to explain why the risks of COVID-19 vary between different ethnic groups and are lowest among white people. This is particularly the case when we compare it with other forms of viral pneumonia that do not lead to such a difference.

The study that found BAME people in England were more likely to die from the disease accounted for differences in some underlying health conditions that are strongly linked to social issues, suggesting these werent the main factor. But the preliminary results from another study suggest ethnic minorities arent more likely to die once other factors linked to deprivation are taken into account.

To clarify this issue, its important to examine whether there may be some genetic component that predisposes ethnic minorities to a higher risk to COVID-19, while still recognising the critical role of other factors.

The way peoples immune systems work depends on genetic factors, not just environmental and social ones. There are effectively two parts to our immune systems. One is the part that produces antibodies, called the adaptive immune system. When our body has never seen a virus before, it can take several days for it to produce them, which is why some people get sick in the first place.

We also have an innate immune system that acts before our body has had time to make antibodies. This system is strong in children and young people, but not very good after the age of 65. This is likely to be one reason why older people are at higher risk of dying of COVID-19.

When a virus like the coronavirus SARS-CoV-2 enters a cell, molecules called toll-like receptors, or TLRs, alert the immune system that something potentially harmful is present. Interestingly, many of the bodys TLRs that can detect viruses come from genetic instructions found in the X chromosome, for which men have only one copy and women two.

We know that women can have a more effective innate immune response to other viruses such as HIV than men, and that oestrogen, the female hormone, enhances this type of immune response. We also know that women are less likely to die from COVID-19 than men.

Just as there are variations in DNA that are responsible for the differences in response of immune cells between the sexes, there can also be variations between people of different ethnic backgrounds. For example, the amount and type of genes that immune cells produce when the TLR-virus pathway is stimulated, are very different between people of African and of European origin.

This is not surprising, because we know that human populations from different parts of the planet have had to adapt to different types of infections. Ethnic differences in the risk to other respiratory viral diseases have been linked to genetic variation, and these variants are different in BAME groups and white people in these same pathways. However, the role of ethnicity in genetic susceptibility to viral diseases is still controversial.

We want to see if it could be a factor in the higher rate of BAME deaths from COVID-19. To do this, we are taking blood from frontline healthcare workers of a variety of ethnic backgrounds, assessing DNA differences and measuring the various substances the samples contain. The results could indicate if differences in the innate immune systems of BAME groups result in higher risk of developing severe COVID-19.

If there is some genetic element to the different death rates from COVID-19 between ethnic groups, its important that we understand it to give us the best chance of fighting the disease. For example, if we do find that the way the innate immune system works plays a role, we can advise people on ways to improve that system, such as through what we eat.

But that wont change the fact that the generally worse health among BAME groups in western societies is strongly linked to socioeconomic factors that are known to play a very significant role in this pandemic.

Read more:
Coronavirus: BAME deaths urgently need to be understood, including any potential genetic component - The Conversation UK

Good science fiction has always been based in truth. George Lucas borrowed from the history of World War II for the look and feel of the original Star Wars trilogy, even Mary Shellys Frankenstein, the first of the genre,* is steeped in allegory for the world she lived in.

But what about the accuracy of the science used in sci-fi? Some movies use a lot of suspension of disbelief, bad physics and downright poor research to propel their storyline forward.

While bad science in science fiction isnt necessarily bad to watch, here are some movies that get a lot right and some that really miss the mark.

These are not documentaries and should not be treated as such. They are Hollywoodized for the sake of audience attention spans and to make things more interesting.

(*Some cite Lady Margaret Cavendish as the spark for science fiction as a genre with her 1666 novel The Blazing World. Bottom line, the genre was pretty much invented by women, the gender most widely underrepresented throughout the genre, but thats another list.)

The Best

Keir Dullea in a scene from 2001: A Space Odyessy (1968).

2001: A Space Odyssey (1968) What is this movie about? A lot of things, and apparently according to director/writer Stanley Kubrick and co-writer Arthur C. Clarke, if you can figure it all out, they failed to do their jobs. Suffice it to say, the classic sci-fi movie is full of not only well-predicted events and ideas of the future (corporate sponsorship, commercial spaceflight) but it also did a remarkable job of staying as scientifically accurate as it could. Kubrick hired aerospace engineers to design devices in the spacecraft interiors instead of usual prop makers, and artists employed by NASA were hired to design spacesuits and capsules. The result was at first not well-received by audiences or critics but with time it found its place and cemented itself as one of the greatest and most accurate (scientifically speaking) films ever made. Rent it on Amazon Prime, Google Play, iTunes, Vudu and YouTube.

Jodie Foster stars in "Contact" (1997).

Contact (1997) While a lot of sci-fi nerds have a lot of issues with this one mostly due to the ending, which I personally enjoyed Contact has a lot of things going for it. First and foremost, it has a female main character! She is clearly the smartest person in the room, though the dudes around her arent as interested in listening to her. The story follows Dr. Ellie Arroway (Jodie Foster) and her work with the Search for Extraterrestrial Intelligence (SETI) program and her discovery of a radio transmission coming from around the Vega system, which relies on a series of prime numbers to send information from beyond our solar system. The novel the film is based on took an unusual route to existence. Author and scientist Carl Sagan and Ann Druyan worked together to create a screenplay in 1979. When the original film stalled, Sagan turned it into a book, which was then made into the film after his death. The movie that was made follows Sagans original story well along with the science and protocols that exist in real life. Rent it on Amazon Prime, Google Play, iTunes, Vudu and YouTube.

Ethan Hawke in a scene from Gattaca (1997).

Gattaca (1997) The film starring Ethan Hawke, Jude Law and Uma Thurman is a staple in many science classrooms when discussing the subject of genetics. Following the idea that in the near future, parents can choose the genetic makeup of their children, making them more attractive, intelligent, faster, stronger, etc., it becomes more common for children to be conceived this way rather than the old-fashioned route. For the few who are conceived through traditional means, they are looked on as second-class citizens, struggling with diseases or other ailments that would never occur in humans whose genetics have been chosen for them. The movie sparks a great debate between science and nature, and prejudices based on DNA. Stream it on Crackle, Tubi or CBS All Access or rent it from Amazon Prime, Google Play, Vudu or YouTube.

A scene from "Finding Nemo" (2003).

Finding Nemo (2003) Yes, it may be surprising to see the heart-tugging animated movie about a fish is one of the more accurate films, but here it is. Ignoring the truth about real clownfishs ability to switch between using their male or female reproductive traits based on whether the dominant female in the community should die, the rest of the film depicts an unusually high accuracy when it comes to most marine biology and ecology. Fish do travel along the East Australian Current as described in the movie (though not as fast), and clownfish do live in sea anemones (at least the species depicted does), then there are the more subtle accuracies like the rows of sharks teeth, fish communications, even nods to poaching. The heartwarming story surrounds the incredible journey of clownfish Marlin and his search for his son Nemo, who has been scooped up by a diver and taken to Sydney. With the help of a forgetful blue tang fish named Dory, theyll go on the adventure of their lives to find Nemo. Stream it on Disney Plus or rent it from Amazon Prime, Google Play, iTunes, Vudu and YouTube.

Matt Damon stars in "The Martian" (2015).

The Martian (2015) The inciting incident of the film, a major storm that leaves scientist Mark Watney (played by the always steady Matt Damon) behind on Mars, isnt actually possible in real life, and there are a few liberties taken for the sake of drama and aesthetics. But a lot of films use of science is sound. Screenwriter and original novelist Andy Weir took great care to research the ins and outs of orbital mechanics, Martian conditions, spaceflight and botany. The film is a basic survival/rescue story that is well told and compelling throughout as NASA and the Chinese space program work together (what a concept!) to bring the lost astronaut home. Plus there are some great lines including Whatneys Im going to science the s--t outta this. Stream it on Hulu (with Live TV subscription) or rent it from Amazon Prime, Google Play, iTunes, Vudu or YouTube.

The Worst

Ben Affleck and Michael Clarke Duncan in a scene from "Armageddon" (1998).

Armageddon (1998) If you split an asteroid or giant meteorite in two, you will just have two of them to hit the earth. They wont conveniently split and go around it. Its also not a great movie.

Dennis Quaid, left, and Dash Mihok in "The Day After Tomorrow" (2004)

The Day After Tomorrow (2004) Arguably one of the most inaccurate depiction of the laws of thermodynamics and just a bad movie in general, The Day After Tomorrow ignores so many facts for the sake of drama its hard to list them all here. One of the main points is that the great freeze and sudden glaciation of the planet comes from a discovery on the part of paleoclimatologist Jack Hall (Dennis Quaid) that the Atlantic meridional overturning circulation current, which brings warm air from the equatorial tropics, has failed and this will cause another ice age. While the current is now known to be slowing down, and the climate of Western Europe will be drastically affected by it, its going to take around 400 years for that to happen. What follows in the film is even more egregious: Giant and impossible storms across the planet aid in triggering the ice age, ice sheets in Greenland melt suddenly and ocean levels rise at a laughable level. Then when the ice does form, the oceans dont then recede as normal physics dictates.

Sandra Bullock in a scene from Gravity (2013).

Gravity (2013) Between implausible events and just poor research, Gravity sinks into the worst category in terms of how it uses the science its trying to depict. For one, George Clooney is meant to be playing an incredibly adept astronaut, but the way he is portrayed as a braggart who showboats and takes a series of unnecessary risks while out on spacewalks. But the biggest problem comes with a spoiler and how space works. Youve been warned. George Clooney didnt have to die. Not even close to it. When he and Sandra Bullock are tethered, he decides to sacrifice himself and let go, floating off into the abyss. Well, thats not how space works. You cant just let go of something and expect to be flung off into oblivion without being pushed by something. Plus all that Sandra Bullock needed to do was give the rope a slight tug and good ol George would come sailing back up to her.

Sam Neill in a scene from Jurassic Park (1993)

Jurassic Park (1993) I will forever love this film no matter what. Its great and it holds up story-wise and effects-wise. Im not getting into its physical interpretations of some of the dinosaurs within it as it used the information they had available to them at the time. Heres the main thing the movie got wrong though: You really cant get the blood from a fossilized mosquito to give you the DNA patterns needed to replicate a dinosaur. The DNA would be destroyed after about 6 million years, and since the dinos they re-created lived something between 100-200 million years ago, it seems impossible to clone the creatures.

Scarlett Johansson in "Lucy" (2014).

Lucy (2013) The entire premise is based on the old saying that humans only use about 10 percent of their brain capacity and what would happen if someone could access 100% of that power. Well, its wrong from the get-go. Humans use 100% of their brain. Apparently, writer-director Luc Besson knew this and went for it anyway. That didnt make any difference the movie is still a stinker.

See original here:
Movies that got science right and ones that got it oh so wrong - Bend Bulletin

Dublin, May 22, 2020 (GLOBE NEWSWIRE) -- The "Fertility Clinics & Infertility Services Industry (U.S.)" report has been added to ResearchAndMarkets.com's offering.

This 4th edition report examines the $6 billion infertility services/fertility clinics industry.

This loosely regulated baby business grew strongly from 2014 to 2019, boosted both by demand domestically and via medical tourism patients from Europe and China. However, due to the Coronavirus, the industry will be hit hard in 2020, as many clinics shut down for two months and foreign patients are not coming to the U.S. any longer.

ART (assisted reproductive technology) now produces more than 50,000 babies per year in the U.S. via 330,000 IVF procedures, and demand is growing from the ranks of 7+ million infertile women, many of which delayed childbearing due to careers. There are about 450 U.S. fertility clinics, 100+ sperm banks, an unknown number of egg donors, and 1,700 reproductive endocrinologists competing for the business, which is lucrative.In addition, the U.S. market for fertility drugs is worth about $749 million. Only two large chains, IntegraMed and Prelude Fertility exist, as most programs are run by small MD practices or are part of a hospital or University. The market is fragmented, served by mostly small regional clinics.

This 4th edition study examines the nature/evolution of the business, national receipts/growth from 1988 to 2019, 2020 forecast, 2025 forecast, infertile customer demographics, key industry trends, industry regulation, pricing, industry consolidation, insurance coverage, ethical issues, and more. Contains results of the latest (2015-2018) CDC ART survey national data, with IVF success rates and long-term trends, as well as European ART cycles and outlook. The report also examines the nature/size of the U.S. sperm banks, egg donors, and fertility drugs markets, and surrogacy programs.

Key Topics Covered:

1. Introduction

2. Report Scope & Methodology, Sources used

3. Executive Overview of Major Findings

4. Nature & Structure of the Industry

5. Patient Demographics

6. Industry Size and Growth

7. Sperm Banks

8. Egg Donor Market

9. The Fertility Drugs Market

10. Findings of 2016-2018 CDC ART Surveys on Assisted Reproductive Technology

11. Tables and analyses of 2016 report: National Summary

12. Text, analyses & discussion covering these topics: (long-term trend data)

13. List of recent fertility start-up companies.

14. Industry Reference Directory

15. List of adoption and fertility services industry trade groups, associations, surveys, consultants, articles, and other sources.

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/y55htc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More here:
Insights into the Fertility Clinics & Infertility Services Industry in the US to 2025 - Featuring Allan Guttmacher Institute, California Cryobank...

22 May 2020

Hair thinning is when one experiences mild to moderate hair loss for an extended period of time. Your hair loses its volume and gives the appearance of thinner areas of hair on your head.

Hair thinning

This is a concern for most people and many companies such asManual, a UK company offer treatments to combat this.

A lot of factors contribute to hair loss. Medical conditions, genetics, and the aging process have been highlighted many times in the past. However, not many are aware that your diet can play a big part in it too.

In this article, well take a look at how the lack of (or excess) nutrients may be linked with hair thinning.

What is a Nutrient Deficiency?

Nutrient deficiency or malnutrition is when your body does not get enough vitamins or minerals needed to sustain itself. You may picture this happening in only the poverty-ridden places in the world, but dont be surprised that your traditional Western dietcan lack certain nutrients as well.

Now, lets take a look at the nutrients commonly linked to hair loss:

Iron

Iron deficiency is the most common type of nutrient deficiency. Foods rich in iron include beef, chicken liver, and sardines. Contrary to popular belief, vegans and vegetarians arent at a higher risk of iron deficiency if their diets are well-balanced with a reasonable portion of whole grains, legumes, and nuts.

Women of reproductive age are more susceptible to iron deficiency due to excessive blood loss during their menstrual cycles.

Iron is crucial in the process of cell growth. They are a component of an enzyme called ribonucleotide reductase. When iron levels are low, hair follicles may not be able to grow effectively, and the amount of hair you naturally shed every day outpaces the rate in which your hair grows.

Vitamin A

Vitamin A can be found naturally in many of our food sources such as leafy vegetables, eggs, and fish. This vitamin is important in cell growth. Generally speaking, if you follow a Western diet, the risk of vitamin A deficiency is unlikely.

Based on current research, there isnt solid evidence to state that vitamin A deficiency can cause hair thinning. However, high levels of vitamin A can.

According to hairlossdoctors.com, excessive vitamin A causes hair follicles to reach the end of the growth phase quicker and fall off faster than the rate in which the body produces more hair.

Vitamin D

The sunshine vitamin or vitamin D is unique in the sense that it acts similarly to hormones. Currently, research has shown a link between vitamin D deficiency and alopecia areata, a disorder that causes bald patches to form.

Vitamin D encourages hair follicle growth and your hair growth may be negatively affected when you dont have enough of it. A natural way to get your daily dose of vitamin D is to be out and about under the sun for 10-30 minutes multiple days a week followed by a diet consisting, fatty fish, egg yolks, mushrooms, and cheese.

During the colder months where there isnt much daylight, you should consider supplementing yourself with vitamin D, as suggested by the NHS.

Disclaimer

Although there are links between nutrient deficiencies and hair loss, there isnt a lot of evidence that could directly correlate this to hair loss and the advice here should not be taken as medical advice. If you are experiencing thinning hair, you should consult your dermatologist as they will assess their patients on a case-by-case basis.

More here:
Nutrition and Hair Thinning - FemaleFirst.co.uk

We dont know if the intention of the creators of Twitter was the platform to become a place for ongoing discussion of any topics; what seems increasingly evident is that it is the social network of the opinadores. And with their tweets as a speaker, some people become trend by launching their reflections more or less successful.

One of the last to become viral has been Wall Street Wolverinean influencer remarkable with close to 100,000 followers he says that to say that the beauty standards are more stringent in women that in men is have no idea. A little bit of the urge to fight had, it is hard to see another way.

Wolverine is also youtuberwith 300,000 followers on that platform talking about political and economical topics. But yesterday he stressed especially on Twitter for his attempts to prove that being attractive is more difficult for men than for women. And first example, puts Margot Robbie at the side of Chris Hemsworth, perhaps a comparison is ill-chosen.

His meditations include phrases like this: A woman with a balanced diet and exercise you can achieve that physique without too much of a problem with constancy. The physical man are, instead, very advanced. Are physical or many years of training or directly use chemistry to achieve it. Given the fact that in order to be attractive you have to be a weightlifter semi-professional, of course.

Among the thousands of comments, a high percentage despising the words of Wolverine, there is a multitude of girls that argue that even doing exercise and maintaining a healthy diet will not get those bodies Something obvious to anyone familiar with the concepts of metabolism and genetics, but the youtuber refuses to accept as well.

Nor is it easy to follow him in his thread of reasoning: it Is a glimpse of a culture of envy and mediocrity tremendous. Chasing the extraordinary vanagloriar conformismshe says as an apparent response to the criticism he has been receiving and as a meditation end of the thread. Ehm, what?

The fact that put to Angelina Jolie as one of the female examples, suspect that has happened at some time or other the operating room, gives a clue that the argument has, to be generous, points flimsy. As his own formulation to begin with.

Read more:
Is it more difficult to be good that be good? The debate is on Twitter - Play Crazy Game

Welcome back to The Rundown, our daily breakdown on comic news stories we missed from the previous day. Have a link to share? Email our team at rundown@multiversitycomics.com.

In case you missed it, we got an exclusive preview of Sera and the Royal Stars #7.

Nathan W. Pyles Strange Planet will be getting a subscription box from Culturefly, The Pop Insider reports. Fans will be able to get exclusive merchandise inspired by the comic as part of this new subscription box. Each box includes a vinyl figure, an exclusive comic on a canvas print, and five to seven additional items featuring the creatures. The subscription box will launch on June 1.

Via Bleeding Cool, Doctor Who fans were treated to a special comic strip written by James Peaty, illustrated by Mike Collins, and narrated by Richard Ashton, in which fans find out more about Danny Pink. Its unclear when the next series of Doctor Who will premiere, although the show will return in the next year with the special Revolution of the Daleks.

Variety reports that Nick Jonas and Lawrence Fishburne are set to star in AGC Studios The Blacksmith, based on the graphic novel from Kickstart Comics by Malik Evans and Richard Sparkman. Pierre Morel (Taken) will direct from a screenplay adapted by Ben Ripley (Flatliners). Jonas will play Wes Loomis, a go-to weapons expert for the intelligence community, who goes on the run after his lab is destroyed and colleagues are murdered. Fishburne will play Mather, a retired blacksmith, and Loomiss mentor. With the aid of a CIA analyst named Noelle Hazlitt, the trio will embark on a journey that keeps this improbable pair one step ahead of their pursuers in a breathless, action-filled thriller. Production on the film will begin later in 2020.

Via Comicbook.com, Cartoon Network announced that We Bare Bears: The Movie will officially release for purchase on digital platforms on June 8, 2020. This is the first movie for the We Bare Bears franchise, which follows three talking bears as they explore life in the woods and city. In addition to the release date, Cartoon Network has also revealed a poster and trailer. The movie will depict the bears as they make their way to Canada after being chased from their home by antagonist, Agent Trout. Eric Edelstein, Demetri Martin, and Bobby Moynihan star in the movie as the bears Grizz, Ice, and Panda. Agent Trout is voiced by Marc Evan Jackson and many of the shows guest stars will also be featured in the movie. We Bare Bears: The Movie is scheduled to release for purchase on digital platforms for $14.99 on June 8, 2020.

Netflix has released the official trailer for The Old Guard, based on the comic by Greg Rucka and Leandro Fernandez. Like the comic, the movie follows a group of immortal soldiers led by Andy, played by Charlize Theron, who must fight to keep their immortality a secret, or otherwise see their gifts exploited. The film will begin streaming on Netflix on July 10, 2020. You can check out the trailer here.

Deadline reports that Sony has hired Marc Guggenheim to write a script for Jackpot, another installment in the larger Spider-Man Cinematic universe following the Venom franchise, and Jared Letos Morbius. In the comics, Jackpot is Sara Ehret, a scientist, who, while pregnant, is doing gene therapy research and is exposed to Lot 777, a virus that rewrites the DNA in her cells. She becomes imbued with superhuman strength and takes on the name Jackpot. Morbius is scheduled to be released on March 19, 2021, while Venom: Let There Be Carnage is set to hit theaters June 25, 2021.

TV Line reports that ABC has renewed 13 shows on their current lineup, including Stumptown. The TV show is based on the comic book series from creators Greg Rucka and Matthew Southworth, and follows Dex, an army vet turned private detective. Season 1 premiered in September. Its unknown when production will begin on season 2 of Stumptown.

Here is the original post:
The Rundown: May 22, 2020 - Multiversity Comics

The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.

BY Dr. Ian Flinn

The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.

In an interview with CURE, Flinn, the director of lymphoma research at Sarah Cannon Research Institute, discussed the use of CAR T-cells to treat lymphomas, as well as how the ZUMA-2 trial is shaping up to influence the treatment of patients with mantle cell lymphoma.

Transcription:

CURE: I'm curious about the ZUMA-2 trial. I know that you're an investigator on that trial. So, if you could talk a little bit about the drug, what it targets, how it works in the body and where things are with that study so far.

Flinn: ZUMA-2 is a clinical trial looking at a CAR T-cell product that targets CD19, which is an antigen on a lot of lymphomas, in this case mantle cell lymphoma, in patients who have had multiple prior therapies for their mantle cell lymphoma, and who are really no longer responding.

So, in this trial, we administered CAR T-cells to these patients. And after giving them some what's called lymphodepleting chemotherapy, and then infuse the CAR T-cells into the patients, we saw a really pretty remarkable outcome.

First (let me offer) a little bit about what a CAR T-cell is. Its a white blood cell, a lymphocyte, that is harvested from the blood of a patient. It's then sent to a central manufacturing facility, where a gene is inserted into the lymphocyte to have the lymphocyte activate as well as target the lymphoma. In this case, it's targeting that antigen called CD19, that's present on most B cell lymphomas and most all the mantle cell lymphoma, many other types of lymphoma as well.

So, it's a really exciting development in the treatment of all lymphomas and in certain forms of leukemia. A similar CAR T-cell product had previously been shown to be very effective in patients with an aggressive form of lymphoma, known as large cell lymphoma. And studies in that patient population led to the approval of CAR T-cells for patients with diffuse large B-cell lymphoma, who also similarly were not really responding to any agents anymore. The therapy had really run the course of what conventional treatments (could offer). And in that patient population there was about a 40%, what looks like long term cure rate for that patient population, so really fabulous results in large cell lymphoma.

And so, in this trial, this trial ZUMA-2, we're hoping to see similar activity in patients with, again, very difficult-to-treat mantle cell lymphoma, patients who already had standard of care therapies such as a tyrosine kinase inhibitor, and chemo immunotherapy. And we saw very remarkable results. Two-thirds of patients achieved a complete remission in this study, and the follow up is relatively short, but in a subgroup of patients that have been followed for more than two years on, about 40% of patients remain in remission.

So, this would be the first CAR T-cell product that will be available to patients with mantle cell lymphoma?

Right. This would be the first CAR T-cell product that's available for mantle cell lymphoma patients. We hope to see FDA approval sometime this summer. It's been submitted to the FDA for approval, and they have certain timelines that the FDA has to make. And based on that, we know that we should hear the latest by August on whether this drug will be approved.

Is there anything else that people should know about this particular study?

I think the other thing to know is when anybody is looking at any kind of therapy, is what are the risks and benefits of this? It sounds wonderful, augmenting the immune system and you're harnessing the immune system to fight the cancer, which is really what this is doing. But it does have side effects. And, and those side effects are sometimes scary.

There's something called cytokine release syndrome, where basically as I explain it to patients, it's like someone's getting the worst flu of their life. I mean, sometimes they can have fevers as high as 104 (degrees). But when you think about it, that's kind of what we're wanting. We want the immune system to be turned on. We want it to go after this lymphoma, what it thinks is foreign. (But) then we've learned better ways of decreasing those side effects now by using other medications to decrease the incidence and severity of cytokine release syndrome.

The other toxicity is called neurological toxicity, or neurotoxicity, and this can be very disturbing to patients and their family members. Because it can sometimes range from just being a little bit sleepy to people being in a full coma. Luckily, nobody died in this study from this, and we're getting better at intervening earlier to decrease the severity of neurologic toxicity. And so, for the vast majority of patients, it's reversible, but it's definitely something for patients who are considering this (drug) to talk to their doctor about.

Read more here:
CAR T-Cell Therapy a 'Really Exciting' Development in Treatment of Lymphomas - Curetoday.com

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Direct-to-Consumer Genetic Testing market.

Trusted Business Insights presents an updated and Latest Study on Direct-to-Consumer Genetic Testing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Direct-to-Consumer Genetic Testing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Direct-to-Consumer Genetic Testing Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Direct-to-Consumer Genetic Testing MarketIndustry / Sector Trends

Direct-to-Consumer Genetic Testing Market size was valued at USD 831.5 million in 2018 and is expected to witness 15.2% CAGR from 2019 to 2025.

U.S. DTC Genetic Testing Market Size, By Test Type, 2018 & 2025 (USD Million)

Rising prevalence of genetic diseases such as cystic fibrosis and Alzheimers globally is one of the major factors fostering direct-to-consumer genetic testing market growth. According to Global Genes, over 300 million people globally suffer from rare diseases. Recently developed DTC genetic tests allows consumer to identify probability of acquiring a specific genetic disease. Therefore, increasing adoption of DTC genetic testing for early disease detection and identification of genetic diseases will boost the industry growth over forecast timeline.

Increasing demand for personalized medications to treat genetic diseases will positively impact industry growth in forthcoming years. Individuals genome must be tested to develop personalized medicines. This increases the demand for DTC genetic kits since, it provides detailed information about individuals genetic predisposition. As detailed information regarding genetic makeup of individuals is easily available with the use of DTC genetic kits, researchers can easily design and develop personalized medicine that would help in faster patient recovery. Aforementioned factor is expected to drive the industry growth. However, high cost of DTC genetic testing kits may hamper industry growth to some extent during the forecast period.

Market Segmentation, Outlook & Regional Insights: Direct-to-Consumer Genetic Testing Market

Direct-to-Consumer Genetic Testing Market, By Test Type

Predictive testing segment will experience around 17% growth throughout the analysis period. Considerable segmental growth can be associated with rising prevalence of genetic diseases. Recently developed DTC genetic tests help to identify mutations that increase the chances of acquiring specific disease accurately. Surging awareness regarding benefits of such presymptomatic testing has reduced the mortality rates by enabling effective management of disease. Above mentioned factors have stimulated the segmental growth that is predicted to continue over the forecast timeframe.

Ancestry and relationship testing segment accounted for over 43% revenue share in 2018. Increasing awareness regarding ethnicity tests amongst the American and European population has increased the demand for DTC genetic tests. Accuracy and efficiency possessed by these tests has fostered segmental growth. Moreover, ancestry tests developed by companies such as Ancestry.com are user friendly. Availability of robust DTC ancestry tests providing meaningful clinical, genealogical and even forensic information will positively impact the segment growth.

Direct-to-Consumer Genetic Testing Market, By Technology

Targeted analysis segment was valued over USD 310 million in 2018. Targeted analysis is utilized for determining the defects in genes that are responsible for a particular disorder. Targeted genotyping can accurately measure an individuals gene pool that encodes important information regarding various diseases. Targeted analysis can be conducted at significant low cost compared to other available techniques that should augment its adoption rate over forecast timeframe.

Single nucleotide polymorphism segment will experience around 15% growth throughout the forecast period. Single nucleotide polymorphism chips specifically detect changes in single nucleotide that increases the efficiency of tests. For instance, SNP chips utilized for diagnosing hereditary cancers have detected 1300 mutations in BRCA2 genes. Various companies such as Ancestry.com and Color Genomics utilize SNP arrays that analyse gene sequences at a specific resolution and reveal detailed analysis about the defective genes that may in future cause certain disease. Increasing adoption of such advanced SNP chips in DTC testing kits will trigger the segmental growth.

Germany DTC Genetic Testing Market Size, By Technology, 2018 (USD Million)

Direct-to-Consumer Genetic Testing Market, By Region

North America direct-to-consumer genetic testing market accounted for around 39% regional share in 2018. Regional market growth can be attributed to increasing prevalence of genetic diseases. Rare genetic diseases such as thalassemia, hemophilia and anaemia require continuous and critical monitoring. According to CDC, every year more than 1,000 people are affected by thalassemia. Furthermore, American population has higher literacy rate and also, awareness regarding DTC tests is high amongst the American population that augments demand for DTC genetic tests.

Europe is estimated to experience around 15% growth over the coming years. European direct-to-consumer genetic testing market is highly regulated and for carrying out some of the genetic tests through DTC kits, customers are required to have physicians prescription. However, currently, European regulatory bodies are working on improving regulations set on DTC tests due to improved accuracy and efficiency possessed by them. Thus, improvement in regulatory scenario will positively impact regional market growth.

Latin America DTC Genetic Testing Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Direct-to-Consumer Genetic Testing Market

Few of the eminent industry players operating in direct-to-consumer genetic testing market are Ancestry, 23andMe, Color, Family Tree DNA, EasyDNA, Helix, Identigene, Full Genomes, Genesis HealthCare, Karmagenes, MyHeritage, MapMyGenome, Living DNA and Pathway Genomics. Chief industry players implement numerous initiatives such as mergers, acquisitions and new product launch to maintain their market position. Receiving approvals from regulatory bodies for new products will also foster companys revenue share. For instance, in October 2018, 23andme received first U.S. FDA approval for de novotechnology utilized in pharmacogenomic tests. This approval will enable company to launch innovative products, thereby fostering companys growth.

Direct-to-Consumer (DTC) Genetic Testing Industry Viewpoint

Direct-to-consumer genetic testing industry can be traced back to early 2000s. Earlier DTC tests were thought to be convenient as they would allow the patients to access their genetic information without involvement of physician. Although, DTC genetic testing kits had several benefits, in the initial days, they were stringently regulated by regulatory bodies. Regulatory scenario has always been stringent since the introduction of DTC genetic kits in European countries. Currently, there has been change in the regulatory scenario and European countries have started receiving approval for DTC genetic kits. Defects in the DTC kits have been reduced and people have started relying on these kits. DTC genetic testing market is sort of matured in North America due to numerous technological advancements and is still in developing phase in Asian countries. With further advancements in technology, DTC genetic tests industry will experience numerous growth opportunitie

Key Insights Covered: Exhaustive Direct-to-Consumer Genetic Testing Market1. Market size (sales, revenue and growth rate) of Direct-to-Consumer Genetic Testing industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Direct-to-Consumer Genetic Testing industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Direct-to-Consumer Genetic Testing industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Direct-to-Consumer Genetic Testing industry.

Research Methodology: Direct-to-Consumer Genetic Testing Market

Quick Read Table of Contents of this Report @ Direct-to-Consumer Genetic Testing Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the rest here:
Direct-to-Consumer Genetic Testing Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Cole of Duty

Direct-To-Consumer Genetic Testing Market 2020 report share informative data figures as well as important insights regarding some of the market component which is considered to be future course architects for the market. This includes factors such as market size, market share, market segmentation, significant growth drivers, market competition, different aspects impacting economic cycles in the market, demand, expected business up-downs, changing customer sentiments, key companies operating in the Direct-To-Consumer Genetic Testing Market, etc. In order to deliver a complete understanding of the global market, the report also shares some of the useful details regarding regional as well as significant domestic markets. The report presents a 360-degree overview and SWOT analysis of the competitive landscape of the industries.

Top Key players of Direct-To-Consumer Genetic Testing Market Covered In The Report:AncestryColorEasyDNAFamily Tree DNAFull GenomesGenesis HealthCareHelixIdentigeneKarmagenesLiving DNAMapMyGenome. Key Market Segmentation of Direct-To-Consumer Genetic Testing:

Market by Test Type

(Ancestry & Relationship Testing, Carrier Testing, Predictive Testing, and Nutrigenomics Testing)

Technology

(Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, and Whole Genome Sequencing (WGS))

Direct-To-Consumer Genetic Testing Market Region Mainly Focusing:

Europe Direct-To-Consumer Genetic Testing Market (Austria, France, Finland, Switzerland, Italy, Germany, Netherlands, Poland, Russia, Spain, Sweden, Turkey, UK), Asia-Pacific and Australia Direct-To-Consumer Genetic Testing Market (China, South Korea, Thailand, India, Vietnam, Malaysia, Indonesia, and Japan), The Middle East and Africa Direct-To-Consumer Genetic Testing Market (Saudi Arabia, South Africa, Egypt, Morocco, and Nigeria), Latin America/South America Direct-To-Consumer Genetic Testing Market (Brazil and Argentina), North America Direct-To-Consumer Genetic Testing Market (Canada, Mexico, and The USA)

Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand.

Buy Full Report Now @ https://www.qurateresearch.com/report/buy/HnM/direct-to-consumer-genetic-testing-market/QBI-CMR-HnM-738584/

(A free report data (as a form of Excel Datasheet) will also be provided upon request along with a new purchase.)

Key Highlights from Direct-To-Consumer Genetic Testing Market Study:

Income and Sales Estimation Historical Revenue and deals volume is displayed and supports information is triangulated with best down and base up ways to deal with figure finish market measure and to estimate conjecture numbers for key areas shrouded in the Direct-To-Consumer Genetic Testing report alongside arranged and very much perceived Types and end-utilize industry. Moreover, macroeconomic factor and administrative procedures are discovered explanation in Direct-To-Consumer Genetic Testing industry advancement and perceptive examination.

Assembling Analysis The Direct-To-Consumer Genetic Testing report is presently broke down concerning different types and applications. The Direct-To-Consumer Genetic Testing market gives a section featuring the assembling procedure examination approved by means of essential data gathered through Industry specialists and Key authorities of profiled organizations.

Competition Analysis Direct-To-Consumer Genetic Testing Leading players have been considered relying upon their organization profile, item portfolio, limit, item/benefit value, deals, and cost/benefit.

Demand and Supply and Effectiveness Direct-To-Consumer Genetic Testing report moreover gives support, Production, Consumption and (Export and Import).

Major Points Covered in Table of Contents:

Direct-To-Consumer Genetic Testing Market OverviewMarket Competition by ManufacturersProduction Market Share by RegionsConsumption by RegionsGlobal Direct-To-Consumer Genetic Testing Production, Revenue, Price Trend by TypeGlobal Direct-To-Consumer Genetic Testing Market Analysis by ApplicationsCompany Profiles and Key Figures in Direct-To-Consumer Genetic Testing BusinessDirect-To-Consumer Genetic Testing Manufacturing Cost AnalysisMarketing Channel, Distributors, and CustomersMarket DynamicsGlobal Direct-To-Consumer Genetic Testing Market ForecastResearch Findings and ConclusionMethodology and Data Source

In a word, the Direct-To-Consumer Genetic Testing Market report provides major statistics on the state of the Direct-To-Consumer Genetic Testing industry with a valuable source of guidance and direction for companies and individuals interested in the market. At the end, Direct-To-Consumer Genetic Testing Market Report delivers a conclusion which includes Research Findings, Market Size Evaluation, Global Market Share, Consumer Needs along with Customer Preference Change, Data Source. These factors will raise the growth of the business overall.

Contact Us:

Web:www.qurateresearch.comE-mail:[emailprotected]Ph: US +13393375221

Note: In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Read more:
Direct-To-Consumer Genetic Testing Market 2020 | Covid19 Impact Analysis | Business Outlook, Growth, Revenue, Trends and Forecasts 2027 - Cole of Duty

The global Direct-To-Consumer (DTC) Genetic Testing market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Direct-To-Consumer (DTC) Genetic Testing market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Direct-To-Consumer (DTC) Genetic Testing market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Direct-To-Consumer (DTC) Genetic Testing market. The Direct-To-Consumer (DTC) Genetic Testing market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2637644&source=atm

The key players covered in this studyAncestryColor GenomicsEasy DNAFamilytreeDNA (Gene By Gene)Full Genome CorporationHelix OpCo LLCIdentigeneKarmagenesLiving DNAMapmygenomeMyHeritagePathway GenomicsGenesis Healthcare23andMe

Market segment by Type, the product can be split intoCarrier TestingPredictive TestingAncestry & Relationship TestingNutrigenomics TestingOthersMarket segment by Application, split intoOnline PlatformsOver-the-Counter

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Direct-To-Consumer (DTC) Genetic Testing status, future forecast, growth opportunity, key market and key players.To present the Direct-To-Consumer (DTC) Genetic Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Direct-To-Consumer (DTC) Genetic Testing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2637644&source=atm

The Direct-To-Consumer (DTC) Genetic Testing market research covers an exhaustive analysis of the following data:

The Direct-To-Consumer (DTC) Genetic Testing market research addresses critical questions, such as

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2637644&licType=S&source=atm

The global Direct-To-Consumer (DTC) Genetic Testing market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

Read the rest here:
COVID-19: Responding to the business impacts of Good Growth Opportunities in Global Direct-To-Consumer (DTC) Genetic Testing Market - Cole of Duty